



The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): Overview and results of the research prioritisation process.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-004905
Article Type:	Research
Date Submitted by the Author:	21-Jan-2014
Complete List of Authors:	Rowe, Fiona; University of Liverpool, Health Services Research Wormald, Richard Cable, Richard Acton, Michele Bonstein, Karen Bowen, Michael Bronze, Carol Bunce, Catey Conroy, Dolores Cowan, Katherine Evans, Kathy Fenton, Mark Giles, Heather Gordon, Iris Halfhide, Louise Harper, Robert Lightstone, Anita Votruba, Marcela Waterman, Heather Zekite, Antra
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Ophthalmology, Qualitative research
Keywords:	Sight loss, Vision, Research, Priorities, Partnership, James Lind Alliance

SCHOLARONE™
Manuscripts

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): Overview and results of the research prioritisation process.

Fiona Rowe¹, Richard Wormald^{2,3}, Richard Cable⁴, Michele Acton⁴, Karen Bonstein⁵, Michael Bowen⁶, Carol Bronze⁷, Catey Bunce^{2,3,5}, Dolores Conroy⁴, Katherine Cowan⁸, Kathy Evans⁹, Mark Fenton¹⁰, Heather Giles⁷, Iris Gordon³, Louise Halfhide⁵, Robert Harper¹¹, Anita Lightstone¹², Marcela Votruba¹³, Heather Waterman¹⁴, Antra Zekite²

1. British and Irish Orthoptic Society
2. Moorfields Eye Hospital NHS Foundation Trust
3. The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine
4. Fight for Sight
5. NIHR Moorfields Biomedical Research Centre for Ophthalmology
6. College of Optometrists
7. Patient representative
8. The James Lind Alliance (JLA) –National Institute for Health Research
9. Royal College of Ophthalmologists
10. UK DUETs (NICE Evidence – UK Database of Uncertainties about the Effects of Treatments)
11. Manchester Royal Eye Hospital
12. UK Vision Strategy / VISION 2020 UK
13. Cardiff University
14. University of Manchester

Corresponding author:

Dr Fiona Rowe

Department of Health Services Research,

Whelan Building (1.10),

University of Liverpool,

1
2
3 Brownlow Hill,
4

5 Liverpool L69 3GB
6

7
8 T: 0151 7944956
9

10 E: rowef@liverpool.ac.uk
11

12
13
14
15 **Word count:** 3514
16

17
18 **Number of figures:** 2
19

20
21 **Number of tables:** 2
22

23 **Short title:** Sight Loss and Vision Priority Setting Partnership
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: The Sight Loss and Vision Priority Setting Partnership aimed to identify research priorities relating to sight loss and vision through consultation with patients, carers and clinicians. These priorities can be used to inform funding bodies decisions and enhance the case for additional research funding.

Design: Prospective survey with support from the James Lind Alliance.

Setting: UK wide NHS and non-NHS.

Participants: Patients, carers and eye health professionals. Academic researchers were excluded. The survey was disseminated by patient groups, professional bodies, at conferences and through the media, and was available for completion online, by phone, by post and by alternative formats (Braille and audio).

Outcome measure: People were asked to submit the questions about prevention, diagnosis and treatment of sight loss and eye conditions that they most wanted to see answered by research. Returned survey questions were reviewed by a data analysis group and out of scope/duplicate/answered questions removed. The remaining questions went through an interim prioritisation process. The top priorities were established across eye disease categories at final workshops.

Results: 2,220 people responded generating 4,461 submissions. Sixty-five percent of respondents had sight loss and/or an eye condition. Following initial data analysis, 686 submissions remained which were circulated for interim prioritisation (excluding cataract and ocular cancer questions) to 446 patients/carers and 218 professionals. The remaining 346 questions were discussed at final prioritisation workshops to reach agreement of top questions per category.

Conclusions: The exercise engaged a diverse community of stakeholders generating a wide range of conditions and research questions. Top priority questions were established across 12 eye disease categories.

Keywords: Sight loss; Vision; Research; Priorities; Partnership; James Lind Alliance

Article summary

Strengths and limitations of this study:

- Wide ranging and comprehensive coverage
- Substantial response
- The hardest to reach and those with the least opportunity to be heard may indeed have not been heard
- Any such groups now feeling excluded should have an opportunity to redress this.

Introduction

In the UK it is estimated that almost 2 million people are affected by sight loss and this number is expected to double by 2050¹. Currently 50% of sight loss in the UK is avoidable but there are also many unavoidable sight loss conditions. Whether it is to address childhood eye conditions or those affecting adults, research is needed to inform us about prevention, to develop new techniques for early diagnosis and to develop new and more effective treatments for many eye conditions.

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP) was developed from earlier work by the Eye Research Group (ERG) of VISION 2020 UK whose mission is the elimination of avoidable sight loss and the amelioration of the effects of sight loss when it cannot be avoided². The UK Vision Strategy sets out ways of addressing avoidable sight loss in the UK. There is much that can be done to improve the nation's eye health, and to eliminate avoidable sight loss. There are however gaps in the evidence base regarding eye health interventions and the best way to deliver services. Research is needed to support the UK Vision Strategy. In key areas research is urgently required to enable the Vision Strategy to be implemented in an evidence-based way that ensures efficient and effective development.

Despite on-going research in the UK and other countries, there are still many questions about the prevention, diagnosis and treatment of sight loss and eye conditions that remain unanswered. Given that resources for research are limited, it

1
2
3 is important for research funders to understand how patients, carers and eye health
4 professionals prioritise these unanswered questions so that future research can be
5 consolidated and targeted accordingly³.
6
7

8
9 The purpose of this project was to undertake a comprehensive, UK-wide, survey of
10 patients, carers and clinicians to identify research questions and priorities to inform
11 decisions of funding bodies and enhance the case for additional research funding.
12
13

14 The priority setting process has been well established by the James Lind Alliance
15 (JLA) (<http://www.lindalliance.org/>) which has supported partnerships on a range of
16 topics since 2004. This partnership initiated by Fight for Sight, the UK's leading eye
17 research charity was established with support, financial and in kind, from the College
18 of Optometrists, the Royal College of Ophthalmologists, the NIHR Biomedical
19 Research Centre for Ophthalmology, the RNIB, UK Vision Strategy and the
20 Cochrane Eyes and Vision Group. A representative from the JLA convened meetings
21 of the steering committee and provided independent chairmanship for this and the
22 priority setting workshops. Their extensive experience in this process ensured no
23 single voice exerted undue influence over the prioritisation process and that the
24 views of patients, their carers and clinicians were paramount. The views of
25 researchers with no clinical involvement with patients and views of commercial
26 organisations were not included.
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Methods and materials**

42 The detailed methods for this prioritisation process have been described in detail
43 elsewhere⁴. In brief, the process comprised five stages (figure 1).
44
45

46 ***Establishing the SLV-PSP***

47
48 A steering committee and data assessment group comprising the authors of this
49 article oversaw the process. Each member was responsible for contributing to and
50 managing a part of the process and was selected for their expertise and association
51 with eye research. The steering committee also included patient representatives
52 and eye health professionals. In April 2012 an initial stakeholder meeting was held to
53 engage the groups and organisations with member bases and community influence.
54
55
56
57
58
59
60

1
2
3 This was to ensure that the initial survey would be disseminated and completed by
4 as many patients, relatives, carers and eye health professionals as possible in the
5 UK.
6
7

8 ***Main survey***

9
10 The SLV-PSP survey was launched on 1 May 2012 and was open until 31 July 2012.
11 The aim of the survey was to identify patients', carers' and eye health professionals'
12 unanswered questions about sight loss and eye conditions. The survey's primary
13 question was "What question(s) about the prevention, diagnosis and treatment of
14 sight loss and eye conditions would you like to see answered by research?"
15
16
17
18
19

20 ***Data analysis***

21
22 Following closure of the survey, all submissions were examined. Out-of-scope
23 submissions were removed including those not related to the topic and uncertainties
24 better suited to social research. In-scope uncertainties were allocated into disease-
25 specific groups and re-worded in PICO format (Population, Intervention,
26 Comparison, Outcome). Searches were then undertaken to ascertain whether or not
27 each uncertainty could be answered by an up-to-date systematic review. All
28 unanswered uncertainties were then allocated to one of 12 eye disease categories,
29 with duplicates removed and similar questions combined. The 12 categories were
30 formed following discussions by the steering group on the most logical and
31 pragmatic way to organise the data within the time and resources available.
32
33
34
35
36
37
38
39

40 ***Interim prioritisation***

41
42 In order to start reducing the number of uncertainties, an interim prioritisation
43 exercise was conducted over email and by post. Patients, carers and eye health
44 professionals were invited to examine the long lists and then choose and rank 10 of
45 the uncertainties.
46
47
48
49

50 ***Final prioritisation***

51
52 The remaining uncertainties were ranked by patients, carers, relatives, organisation
53 representatives and eye health professionals in one-day workshops facilitated by the
54 JLA, using Nominal Group Technique – a mix of discussion and ranking. For each
55 category, the top 10/11 questions were agreed.
56
57
58
59
60

Results

Main survey

In response to the survey, 2220 people generated 4461 submissions. Of these respondents, 17% identified themselves as healthcare professionals including primarily ophthalmologists, optometrists, orthoptists, ophthalmic nurses, opticians and people working in social care and rehabilitation (figure 2). Over 60% were people with sight loss or an eye condition. The average age of survey participants was 65.7 years old (range:16 months (proxy completion of survey by adult carer)to 105 years). Just under two thirds (62%) of respondents were female. The geographical split was: England 89%; Scotland 6%; Wales 4%; Northern Ireland 1%.

Data analysis

Following data analysis to remove duplicate/answered/out of scope uncertainties, 686 uncertainties remained. These were divided into twelve eye disease categories. Table 1 shows each category with the initial number of submissions received after the survey responses were submitted, the number of uncertainties sent to interim prioritisation, the number of participants at interim prioritisation and the number of uncertainties considered at the final prioritisation workshops.

Interim prioritisation

Respondents from the initial survey, organisations and eye healthcare professionals with expertise in the eye diseases in ten categories were contacted to provide interim priority rankings. The smaller number of questions asked in the categories relating to cataract and ocular cancer meant that an interim prioritisation exercise was not required for either category. A large response was received for the interim exercise, with input from 446 patients, carers and relatives plus 218 eye health professionals. Uncertainties accumulated scores based on rank and frequency, resulting in short lists of around 30 uncertainties per category which were taken to final workshops.

Final prioritisation

In April and May 2013, 12 final prioritisation workshops were held: one for each eye disease category. Balanced numbers of patients/carers/relatives and eye health professionals participated. In total, 155 participants attended across all 12 workshops: 78 patients and 77 clinicians (table 2). The topics debated at each workshop comprised between 19-31 questions per category. Overall 153 questions about sight loss and vision were considered resulting in lists of 10/11 priorities for each of the 12 categories:

Age-related macular degeneration

1. Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised?
2. What is the cause of AMD?
3. How can AMD be prevented?
4. Are there ways of restoring sight loss for people with AMD?
5. Can the development of AMD be predicted?
6. What is the most effective way to detect and monitor the progression of early AMD?
7. What factors influence the progression of AMD?
8. Can a non-invasive therapy be developed for wet AMD?
9. Can dietary factors, nutritional supplements, complementary therapies or lifestyle changes prevent or slow the progression of AMD?
10. What are the best enablement strategies for people with AMD?

Cataract

1. How can cataracts be prevented from developing?
2. Can the return of cloudy or blurred vision after cataract surgery known as posterior capsule opacity (PCO) or secondary cataract be prevented?
3. How can cataract progression be slowed down?
4. What alternatives to treat cataracts other than cataract surgery are being developed?
5. What is the cause of cataract?
6. How can cataract surgery outcomes be improved?
7. How safe and effective is laser assisted cataract surgery?
8. Should accommodative lenses be developed for cataract surgery?

- 1
- 2
- 3 9. What is the best measure of visual disability due to cataract?
- 4 10. Can retinal detachment be prevented after cataract surgery?
- 5
- 6 11. What are the outcomes for cataract surgery among people with different
- 7 levels of cognitive impairment (whatever the cause but including dementia,
- 8 stroke, neurological conditions, head injuries)?
- 9
- 10

Childhood-onset disorders

- 11
- 12
- 13
- 14 1. How can cerebral visual impairment be identified, prevented and treated in
- 15 children?
- 16
- 17 2. How can treatment for visual pathway damage associated with pre-term birth
- 18 be developed?
- 19
- 20 3. How do we improve screening and surveillance from the ante-natal period
- 21 through to childhood to ensure early diagnosis of impaired vision and eye
- 22 conditions?
- 23
- 24 4. Can the treatment of amblyopia be improved to produce better short and long
- 25 term outcomes than are possible with current treatments?
- 26
- 27 5. How can cataract be prevented in children?
- 28
- 29 6. What are the causes of coloboma and microphthalmia/anophthalmia and how
- 30 can they be prevented?
- 31
- 32 7. Can vision be corrected in later life for people with amblyopia?
- 33
- 34 8. How can retinoblastoma be identified, prevented and treated in children?
- 35
- 36 9. Can better treatments for glaucoma in children be developed?
- 37
- 38 10. Can a treatment be developed to improve vision for people with albinism?
- 39
- 40

Corneal and external diseases

- 41
- 42
- 43 1. Can new therapies such as gene or stem cell treatments be developed for
- 44 corneal diseases?
- 45
- 46 2. What is the most effective management for dry eye and can new strategies be
- 47 developed?
- 48
- 49 3. Can treatments to save eye sight from microbial keratitis be improved?
- 50
- 51 4. How can the rejection of corneal transplants be prevented?
- 52
- 53 5. Can the outcomes of corneal transplantation be improved?
- 54
- 55 6. What causes keratoconus to progress and can progression be prevented?
- 56
- 57 7. Can non-surgical therapy be developed for Fuchs' corneal dystrophy?
- 58
- 59
- 60

8. Can corneal infections be prevented in high-risk individuals such as contact lens wearers?
9. What is the cause of keratoconus and can it be prevented?
10. What is the most effective management of ocular complications associated with Stevens Johnson Syndrome?
11. Can severe ocular surface disease in children, such as blepharokeratoconjunctivitis and vernal keratoconjunctivitis be managed better?

Glaucoma

1. What are the most effective treatments for glaucoma and how can treatment be improved?
2. How can loss of vision be restored for people with glaucoma?
3. How can glaucoma be stopped from progressing?
4. What can be done to improve early diagnosis of sight-threatening glaucoma?
5. What causes glaucoma?
6. What is the most effective way of monitoring the progression of glaucoma?
7. How can glaucoma patients with a higher risk to progress rapidly be detected?
8. Why is glaucoma more aggressive in people of certain ethnic groups, such as those of West African origin?
9. How can glaucoma be prevented?
10. Is there a link between treatment adherence and glaucoma progression and how can adherence be improved?

Inherited retinal diseases

1. Can a treatment to slow down progression or reverse sight loss in inherited retinal diseases be developed?
2. How can sight loss be prevented in an individual with inherited retinal disease?
3. Is a genetic (molecular) diagnosis possible for all inherited retinal diseases?
4. What factors affect the progression of sight loss in inherited retinal diseases?
5. What causes sight loss in inherited retinal diseases?
6. What is the most effective way to support patients with inherited retinal disease?

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
7. Can the diagnosis of inherited retinal diseases be refined so that individuals can be given a clearer idea about their specific condition and how it is likely to progress?
 8. What is the relationship between sight loss and mental health for people with inherited retinal diseases?
 9. Would having a treatment for an inherited retinal disease preclude a patient from having another treatment?
 10. With regard to inherited retinal diseases what is the role of pre-natal and pre-implantation diagnosis in helping parents make informed choices?

Neuro-ophthalmology

1. What is the underlying cause of optic nerve damage in optic neuropathies, such as anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?
2. What are the most effective treatments and rehabilitation for optic neuropathies, e.g. Leber's hereditary optic neuropathy and anterior ischaemic optic neuropathy?
3. Can vision loss due to optic nerve diseases such as giant cell arteritis, Leber's hereditary optic neuropathy, optic neuritis and optic atrophy, be restored, for example through gene therapy and stem cell treatment?
4. What rehabilitation or treatment methods are most effective for vision loss following brain damage due to stroke, brain injury, cerebral vision impairment, tumours and dementias?
5. What is the most effective way to assess vision in patients with neurological visual impairment i.e. stroke, dementia and cerebral/cortical visual impairment?
6. Can the early stages of optic neuropathy be detected?
7. How can optic neuropathies be prevented, for example anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?
8. Can treatments be developed for visual field and ocular motility manifestations following stroke?
9. How can electronic devices improve or restore vision for people with optic neuropathies?

10. Can an alternative or new treatment be developed that will treat the sight loss caused by giant cell arteritis?

Ocular cancer

1. What can be done to help ocular cancer sufferers?
2. Can gene-based targeted therapies for ocular cancers be developed?
3. How can immunotherapy be used to fight metastatic ocular melanoma?
4. What are the most effective detection and screening methods for follow up to detect metastasis of ocular melanoma?
5. How can follow-up for ocular complications be managed in patients with ocular melanoma?
6. What is the best management of metastatic choroidal melanoma?
7. What activates choroidal melanoma metastasis in the liver after the primary melanoma has been treated?
8. Can adjuvant therapies be developed to treat ocular melanoma?
9. What are the causes of ocular cancer and how can they be prevented?
10. What is the most effective treatment for primary ocular melanoma?

Ocular inflammatory diseases

1. What are the most effective treatments for ocular and orbital inflammatory diseases?
2. What causes thyroid eye disease?
3. Can the severity of ocular and orbital inflammatory disease in an individual be predicted?
4. Is it possible to prevent further occurrences of retinal damage caused by toxoplasmosis?
5. What causes birdshot retinopathy?
6. Why does disease burn out in patients with ocular and orbital inflammatory diseases?
7. Can early detection methods be developed for ocular and orbital inflammatory diseases?
8. What medications best prevent the development of eye disease in Behcets?
9. What causes scleritis?
10. Can diet or lifestyle changes prevent uveitis from developing?

Refractive error and ocular motility

- 1
- 2
- 3 1. What factors influence the development of refractive error (myopia,
- 4 astigmatism, presbyopia and long-sightedness)?
- 5
- 6 2. What is the cause of both congenital and acquired nystagmus?
- 7
- 8 3. How can the development of binocular vision in young children with squint
- 9 and amblyopia be promoted, and would the same approach work in older
- 10 individuals without inducing intractable diplopia?
- 11
- 12 4. Would correction of refractive error have a positive impact on early life
- 13 learning and development?
- 14
- 15 5. Does early diagnosis of refractive error improve long-term prognosis and
- 16 promote faster, more effective treatment?
- 17
- 18 6. What is the effect of congenital nystagmus on visual and emotional
- 19 development?
- 20
- 21 7. What is the most effective treatment for exotropia and when should it be
- 22 delivered?
- 23
- 24 8. How can the functional effects of surgical treatment for squint best be
- 25 assessed?
- 26
- 27 9. Could the accurate testing of refractive error be made less dependent on a
- 28 subjective response i.e. the person's own response?
- 29
- 30 10. How can myopia be prevented?
- 31
- 32
- 33
- 34

Retinal vascular diseases

- 35
- 36
- 37 1. What are the best methods to prevent retinopathy of prematurity?
- 38
- 39 2. How can sight loss from diabetic retinal changes be prevented and reduced?
- 40
- 41 3. What are the predictive factors for the progression to sight threatening
- 42 diabetic eye disease?
- 43
- 44 4. Is there a way to improve screening of premature babies for retinopathy of
- 45 prematurity?
- 46
- 47 5. Can an effective long lasting treatment for diabetic macular oedema, both
- 48 ischaemic and non-ischaemic, be developed?
- 49
- 50 6. Can a retinal vein occlusion be predicted and prevented?
- 51
- 52 7. Can new non-invasive treatments be developed to slow down the progression
- 53 of diabetic retinopathy?
- 54
- 55 8. What are the barriers that prevent diabetic patients having regular eye
- 56 checks?
- 57
- 58
- 59
- 60

9. What rehabilitation programmes are best for the management of distorted vision from retinal diseases?
10. What is the efficacy and safety of anti-VEGF agents in the treatment of retinopathy of prematurity?

Vitreoretinal and ocular trauma

1. How can surgical techniques be improved to save sight for eyes damaged by injury?
2. How can the risk of losing sight for people with retinal detachment be reduced?
3. How can better interventions be developed that are effective in treating vitreous opacities/eye floaters?
4. What causes retinal detachment and can it be prevented?
5. Can more effective diagnostic tools be developed for assessing the vitreous and eye floaters?
6. Can a functioning prosthetic eye be developed to replace an eye damaged by injury?
7. How can epiretinal membrane/fibrosis be prevented or treated?
8. Can stem cells be used to regrow an eye or part of an eye?
9. What causes posterior vitreous detachment/vitreous syneresis?
10. Are there methods to prevent and improve the treatment of macular holes?

Discussion

About 50% of sight loss in the UK is currently avoidable¹. Recognising this and the UK's pre-eminent position in eye research, the Vision 2020UK ERG considered that any UK Research Agenda must look at addressing unavoidable sight loss for it to be credible. The challenge was to produce a coherently constructed and constituted prioritised research agenda whose methods were clear and for which there had been inclusive and widespread consultation, where everyone with an interest had been offered the opportunity to contribute and be heard.

The SLV-PSP is unique because it sought the combined views of patients, carers and eye health professionals to identify uncertainties about the prevention, diagnosis and treatment of sight loss and eye conditions and prioritise them for research to

1
2
3 address⁵. It is rare that those with direct experience of conditions are able to
4 influence the research agenda^{3,5,6}. However, this SLV-PSP provided an extensive
5 set of unanswered questions prioritised by patients, carers and eye health
6 professionals across twelve categories of eye conditions. These questions
7 addressed a broad range of eye conditions and considered issues of aetiology,
8 prevention, screening, assessment and management. These may now be used to
9 encourage researchers to investigate what is most important to these groups. Similar
10 to other PSP processes, it is envisaged that research funders will be able to use the
11 list to inform commissioned calls for research and identify which research
12 applications to response mode funding opportunities can answer questions that
13 these groups have agreed are a priority.
14
15

16
17
18
19
20
21
22 The SLV-PSP will also help to increase awareness of why research into sight loss
23 and vision is necessary and important. It will be used to campaign for major funders
24 to invest in sight loss and eye conditions, all of which are placing increased
25 emphasis on researchers demonstrating how they have consulted and involved the
26 public and patients in the process of developing their research.
27
28
29

30
31
32 These remain significant goals. For a sector with around 700 organisations to arrive
33 at any kind of consensus for research priority areas, a process that was genuinely
34 consultative, open and engaging to the individuals whose interests these
35 organisations represent as well as at an organisational level was recognised as
36 being critical. For a prioritisation exercise to be useful to the sector it needed to
37 make sense to funders and statutory bodies with responsibilities and interests in
38 these areas as well as to researchers. It was recognised that a prioritisation of
39 research areas produced by a small group within the sector would not be credible
40 and would never engage the support required for it to achieve the goals listed above.
41
42
43
44
45
46
47
48

49 **Conclusions**

50
51
52 Following a systematic process of national consultation and widespread survey of
53 patients, carers and clinicians, 2220 individuals generated 4461 questions. Through
54 a process of data analysis, interim prioritisation and final workshops, a top ten or
55 eleven research questions have been identified for twelve categories of eye
56
57
58
59
60

1
2
3 conditions. This is the first time, to our knowledge, that an exercise like this has been
4 carried out anywhere in the world for sight loss and vision. Not only is this the most
5 wide ranging and ambitious James Lind Alliance priority setting partnership, it also
6 engaged a diversity of participants and enabled them to reach consensus together.
7
8 For the first time, we have a clear idea of what the consumers of eye research – the
9 patients and the people who care for and treat them – believe research money
10 should be spent on. It has provided a focus for research in sight loss and vision and
11 it is intended that these priorities are used to inform funders, researchers, clinicians
12 and the public.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Funding:** This work was supported through funding and/or in-kind support by
4 College of Optometrists, Fight for Sight, James Lind Alliance, NIHR Moorfields BRC,
5 RNIB, Royal College of Ophthalmologists and UK Vision Strategy.
6
7

8
9 **Author contributions:** FR, RW, RC, MA, KB, MB, CBr, CBu, DC, KC, KE, MF, HG,
10 IG, LH, RH, AL, MV, HW and AZ contributed to the conduct of the survey. FR, RW,
11 RC, MA, MB, DC and KC were involved in the drafting of the paper. KB, CBr, CBu,
12 KE, MF, HG, IG, LH, RH, AL, MV, HW and AZ contributed to proofing of the paper.
13
14


15
16 **Competing interests:** The authors declare that they have no competing interests.
17
18

19 **Data Sharing Statement:** Data sharing statement: All original data are held by Fight
20 for Sight and James Lind Alliance.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Access Economics (2009) Future Sight Loss UK 1: The economic impact of partial sight and blindness in the UK adult population, RNIB
2. <http://www.vision2020uk.org.uk/>
3. Chalmers, I. and Glasziou, P. (2009) 'Avoidable waste in the production and reporting of research evidence', *The Lancet*, Vol. 374, pp. 86–89.
4. Sight loss and vision priority setting partnership. Setting priorities for eye research. (2013) Final report. www.sightlosspsp.org.uk
5. Stewart, R. and Oliver, S. (2008) *A systematic map of studies of patients' and clinicians' research priorities*. London: James Lind Alliance.
6. Caron-Flinterman J, et al. (2006) Patients priorities concerning health research: the case of asthma and COPD research in the Netherlands. *Health Expectations*, 8, pp253–263.

Figure 1 Flowchart of SLVPSP process




For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2 Background of respondents



Review only

BMJ Open: first published as 10.1136/bmjopen-2014-004905 on 23 July 2014. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

Table 1 Categories of eye condition

	Initial number of survey questions	Number of questions at interim prioritisation	Number of participants at interim prioritisation	Number of questions at final prioritisation
Age-related macular degeneration	763	43	101 PPI 25 Professionals	29
Cataract	191	27	Not required	27
Childhood-onset disorders	125	69	12 PPI 20 Professionals	30
Corneal and external diseases	292	93	25 PPI 38 Professionals	30
Glaucoma	1235	78	182 PPI 25 Professionals	30
Inherited retinal diseases	280	63	27 PPI 25 Professionals	30
Neuro-ophthalmology	125	43	15 PPI 21 Professionals	30
Ocular cancer	26	19	Not required	19
Ocular inflammatory diseases	472	66	27 PPI 21 Professionals	30
Refractive error and ocular motility	188	70	21 PPI 23 Professionals	31
Retinal vascular diseases	205	56	15 PPI 12 Professionals	30
Vitreoretinal and ocular trauma	265	59	21 PPI 8 Professionals	30

PPI: Inclusive of patients, carers, relatives, organisation representatives.

Professionals: Inclusive of eye health professions.

Table 2 Final workshop participants

Category	Total number of workshop participants	Number of patients, relatives, carers, patient groups and organisations	Number of eye health professionals
Age-related Macular Degeneration	17	9	8
Cataract	11	5	6
Childhood-Onset Disorders	16	7	9
Corneal and External Diseases	12	5	7
Glaucoma	17	9	8
Inherited Retinal Diseases	19	11	8
Neuro-ophthalmology	10	6	4
Ocular Cancer	10	6	4
Ocular Inflammatory Diseases	10	5	5
Refractive Error and Ocular Motility	12	5	7
Retinal Vascular Diseases	11	3	8
Vitreoretinal and Ocular Trauma	10	7	3
TOTAL	155	78	77

BMJ Open

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): Overview and results of the research prioritisation survey process.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-004905.R1
Article Type:	Research
Date Submitted by the Author:	27-May-2014
Complete List of Authors:	Rowe, Fiona; University of Liverpool, Health Services Research Wormald, Richard; The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine, Eyes and Vision; Moorfields Eye Hospital NHS Foundation Trust, Ophthalmology Cable, Richard; Fight for Sight, Acton, Michele; Fight for Sight, Bonstein, Karen; Institute of Ophthalmology, NIHR Moorfields Biomedical Research Centre for Ophthalmology Bowen, Michael; College of Optometry, Bronze, Carol; Patient representative, Bunce, Catey; Moorfields Eye Hospital NHS Foundation Trust, Ophthalmology; Institute of Ophthalmology, NIHR Moorfields Biomedical Research Centre for Ophthalmology Conroy, Dolores; Fight for Sight, Cowan, Katherine; James Lind Alliance (JLA) –National Institute for Health Research, Evans, Kathy; Royal College of Ophthalmology, Fenton, Mark; UK DUETs (NICE Evidence – UK Database of Uncertainties about the Effects of Treatments), Giles, Heather; Patient representative, Gordon, Iris; The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine, Eyes and Vision Halfhide, Louise; Institute of Ophthalmology, NIHR Moorfields Biomedical Research Centre for Ophthalmology Harper, Robert; Manchester Royal Eye Hospital, Department of Optometry Lightstone, Anita; VISION 2020 UK, UK Vision Strategy Votruba, Marcela; Cardiff University, Department of Ophthalmology Waterman, Heather; University of Manchester, Department of Nursing Zekite, Antra; The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine, Eyes and Vision
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Ophthalmology, Qualitative research
Keywords:	Sight loss, Vision, Research, Priorities, Partnership, James Lind Alliance

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2014-004905 on 23 July 2014. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): Overview and results of the research prioritisation survey process.

Fiona Rowe¹, Richard Wormald^{2,3}, Richard Cable⁴, Michele Acton⁴, Karen Bonstein⁵, Michael Bowen⁶, Carol Bronze⁷, Catey Bunce^{2,3,5}, Dolores Conroy⁴, Katherine Cowan⁸, Kathy Evans⁹, Mark Fenton¹⁰, Heather Giles⁷, Iris Gordon³, Louise Halfhide⁵, Robert Harper¹¹, Anita Lightstone¹², Marcela Votruba¹³, Heather Waterman¹⁴, Antra Zekite²

1. British and Irish Orthoptic Society, London, UK
2. Department of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK
3. The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine, London, UK
4. Fight for Sight, London, UK
5. NIHR Moorfields Biomedical Research Centre for Ophthalmology, Institute of Ophthalmology, London, UK
6. College of Optometrists, London, UK
7. Patient representative
8. The James Lind Alliance (JLA) –National Institute for Health Research, Southampton, UK
9. Royal College of Ophthalmologists, London, UK
10. UK DUETs (NICE Evidence – UK Database of Uncertainties about the Effects of Treatments), London, UK
11. Department of Optometry, Manchester Royal Eye Hospital, Manchester, UK
12. UK Vision Strategy / VISION 2020 UK, London, UK
13. Department of Ophthalmology, Cardiff University, Cardiff, UK
14. Department of Nursing, University of Manchester, Manchester, UK

Corresponding author:

Dr Fiona Rowe

Department of Health Services Research,

1
2
3 WhelanBuilding (1.10),
4

5 University of Liverpool,
6

7 Brownlow Hill,
8

9
10 Liverpool L69 3GB
11

12
13 T: 0151 7944956
14

15 E: rowef@liverpool.ac.uk
16
17

18
19
20 **Word count:** 2573
21

22
23 **Number of figures:** 2
24

25
26 **Number of tables:** 3
27

28 **Short title:** Sight Loss and Vision Priority Setting Partnership
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: The Sight Loss and Vision Priority Setting Partnership aimed to identify research priorities relating to sight loss and vision through consultation with patients, carers and clinicians. These priorities can be used to inform funding bodies' decisions and enhance the case for additional research funding.

Design: Prospective survey with support from the James Lind Alliance.

Setting: UK wide NHS and non-NHS.

Participants: Patients, carers and eye health professionals. Academic researchers were excluded solely from the prioritisation process. The survey was disseminated by patient groups, professional bodies, at conferences and through the media, and was available for completion online, by phone, by post and by alternative formats (Braille and audio).

Outcome measure: People were asked to submit the questions about prevention, diagnosis and treatment of sight loss and eye conditions that they most wanted to see answered by research. Returned survey questions were reviewed by a data assessment group. Priorities were established across eye disease categories at final workshops.

Results: 2,220 people responded generating 4,461 submissions. Sixty-five percent of respondents had sight loss and/or an eye condition. Following initial data analysis, 686 submissions remained which were circulated for interim prioritisation (excluding cataract and ocular cancer questions) to 446 patients/carers and 218 professionals. The remaining 346 questions were discussed at final prioritisation workshops to reach agreement of top questions per category.

Conclusions: The exercise engaged a diverse community of stakeholders generating a wide range of conditions and research questions. Top priority questions were established across 12 eye disease categories.

Keywords: Sight loss; Vision; Research; Priorities; Partnership; James Lind Alliance

Article summary

Strengths and limitations of this study:

- Wide ranging and comprehensive coverage
- Substantial response
- The hardest to reach and those with the least opportunity to be heard may indeed have not been heard
- Any such groups now feeling excluded should have an opportunity to redress this.

Introduction

In the UK it is estimated that almost 2 million people are affected by sight loss and this number is expected to double by 2050¹. Currently 50% of sight loss in the UK is avoidable but there are also many unavoidable sight loss conditions. Whether it is to address childhood eye conditions or those affecting adults, research is needed to inform us about prevention, to develop new techniques for early diagnosis and to develop new and more effective treatments for many eye conditions.

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP) was developed from earlier work by the Eye Research Group (ERG) of VISION 2020 UK whose mission is the elimination of avoidable sight loss and the amelioration of the effects of sight loss when it cannot be avoided². The UK Vision Strategy sets out ways of addressing avoidable sight loss in the UK. There is much that can be done to improve the nation's eye health, and to eliminate avoidable sight loss. There are however gaps in the evidence base regarding eye health interventions and the best way to deliver services. Research is needed to support the UK Vision Strategy. In key areas research is urgently required to enable the Vision Strategy to be implemented in an evidence-based way that ensures efficient and effective development.

Despite on-going research in the UK and other countries, there are still many questions about the prevention, diagnosis and treatment of sight loss and eye conditions that remain unanswered. Given that resources for research are limited, it is important for research funders to understand how patients, carers and eye health professionals prioritise these unanswered questions so that future research can be consolidated and targeted accordingly³.

1
2
3 The purpose of this project was to undertake a comprehensive, UK-wide, survey of
4 patients, carers and clinicians to identify research questions and priorities to inform
5 decisions of funding bodies and enhance the case for additional research funding.
6
7

8
9 The priority setting process has been well established by the James Lind Alliance
10 (JLA) (<http://www.lindalliance.org/>) which has supported partnerships on a range of
11 topics since 2004. This partnership initiated by Fight for Sight, the UK's leading eye
12 research charity was established with support, financial and in kind, from the College
13 of Optometrists, the Royal College of Ophthalmologists, the NIHR Biomedical
14 Research Centre for Ophthalmology, the RNIB, UK Vision Strategy and the
15 Cochrane Eyes and Vision Group. A representative from the JLA convened meetings
16 of the steering committee and provided independent chairmanship for this and the
17 priority setting workshops. Their extensive experience in this process ensured no
18 single voice exerted undue influence over the prioritisation process and that the
19 views of patients, their carers and clinicians were paramount. The views of
20 researchers with no clinical involvement with patients and views of commercial
21 organisations were not included in the prioritisation.
22
23
24
25
26
27
28
29
30
31
32
33

34 **Methods and materials**

35
36 The detailed methods for this prioritisation process have been described in detail
37 elsewhere⁴. In brief, the process comprised five stages (figure 1). Our study did not
38 require ethical approval or consent from participants. James Lind Alliance priority
39 setting partnerships do not require ethical approval. Dissemination of the survey is
40 via open communications through professional bodies, charities and related
41 organisations. The survey is not undertaken through Higher Education Institutes or
42 through NHS organisations and does not recruit NHS patients. The survey contains
43 clear information on the aims of the priority setting partnership, how the process
44 works and how data will be used. In addition, submission of questions is
45 anonymised. For the workshops in which priorities were discussed and agreed,
46 participants choose to voluntarily attend and consent is not required for this. We
47 followed the ethical guidance for participation, information and evaluation from the
48 James Lind Alliance guidebook (<http://www.jla-guidebook.org/jla-guidebook.asp?val=56>).
49
50
51
52
53
54
55
56
57
58
59
60

Establishing the SLV-PSP

A steering committee and data assessment group comprising the authors of this article oversaw the process. Each member was responsible for contributing to and managing a part of the process and was selected for their expertise and association with eye research. The steering committee also included patient representatives and eye health professionals. In April 2012 an initial stakeholder meeting was held to engage the groups and organisations with member bases and community influence. This was to ensure that the initial survey would be disseminated and completed by as many patients, relatives, carers and eye health professionals as possible in the UK.

Main survey

The SLV-PSP survey was launched on 1 May 2012 and was open until 31 July 2012. The aim of the survey was to identify patients', carers' and eye health professionals' unanswered questions about sight loss and eye conditions. The survey's primary question was "What question(s) about the prevention, diagnosis and treatment of sight loss and eye conditions would you like to see answered by research?"

Data analysis

Following closure of the survey, all submissions were examined. Out-of-scope submissions were removed including those not related to the topic and uncertainties better suited to social research. In-scope uncertainties were allocated into disease-specific groups and re-worded in PICO format (Population, Intervention, Comparison, Outcome). Searches were then undertaken to ascertain whether or not each uncertainty could be answered by an up-to-date systematic review. All unanswered uncertainties were then allocated to one of 12 eye disease categories, with duplicates removed and similar questions combined. Checks were also made to identify any on-going trials which might address the uncertainty. The 12 categories were formed following discussions by the steering group on the most logical and pragmatic way to organise the data within the time and resources available.

Interim prioritisation

1
2
3 In order to start reducing the number of uncertainties, an interim prioritisation
4 exercise was conducted over email and by post. Patients, carers and eye health
5 professionals were invited to examine the long lists and then choose and rank 10 of
6 the uncertainties.
7
8
9

10 ***Final prioritisation***

11
12 The remaining uncertainties were ranked by patients, carers, relatives, organisation
13 representatives and eye health professionals in one-day workshops facilitated by the
14 JLA, using Nominal Group Technique – a mix of discussion and ranking. For each
15 category, the top 10/11 questions were agreed.
16
17
18
19
20
21
22

23 **Results**

24 ***Main survey***

25
26 In response to the survey, 2220 people generated 4461 submissions. Of these
27 respondents, 17% identified themselves as healthcare professionals including
28 primarily ophthalmologists, optometrists, orthoptists, ophthalmic nurses, opticians
29 and people working in social care and rehabilitation (figure 2). Over 60% were
30 people with sight loss or an eye condition. The average age of survey participants
31 was 65.7 years old (range:16 months (proxy completion of survey by adult carer)to
32 105 years). Just under two thirds (62%) of respondents were female. The
33 geographical split was: England 89%; Scotland 6%; Wales 4%; Northern Ireland 1%.
34
35
36
37
38
39
40
41

42 ***Data analysis***

43
44 Following data analysis to remove duplicate/answered/out of scope uncertainties,
45 686 uncertainties remained. These were divided into twelve eye disease categories.
46 Table 1 shows each category with the initial number of submissions received after
47 the survey responses were submitted, the number of uncertainties sent to interim
48 prioritisation, the number of participants at interim prioritisation and the number of
49 uncertainties considered at the final prioritisation workshops.
50
51
52
53
54

55 ***Interim prioritisation***

1
2
3 Respondents from the initial survey, organisations and eye healthcare professionals
4 with expertise in the eye diseases in ten categories were contacted to provide interim
5 priority rankings. The smaller number of questions asked in the categories relating to
6 cataract and ocular cancer meant that an interim prioritisation exercise was not
7 required for either category. A large response was received for the interim exercise,
8 with input from 446 patients, carers and relatives plus 218 eye health professionals.
9
10 Uncertainties accumulated scores based on rank and frequency, resulting in short
11 lists of around 30 uncertainties per category which were taken to final workshops.
12

13 ***Final prioritisation***

14
15
16
17
18 In April and May 2013, 12 final prioritisation workshops were held: one for each eye
19 disease category. Balanced numbers of patients/carers/relatives and eye health
20 professionals participated. In total, 155 participants attended across all 12
21 workshops: 78 patients and 77 clinicians (table 2). The topics debated at each
22 workshop comprised between 19-31 questions per category. Overall 153 questions
23 about sight loss and vision were considered resulting in lists of 10/11 priorities for
24 each of the 12 categories (table 3). The questions addressed the broad topics of
25 aetiology, prevention, identification and interventions with the number 1 questions as
26 follows:
27
28
29
30
31
32
33

34 ***Age-related macular degeneration***

- 35
36
37
38 1. Can a treatment to stop dry AMD progressing and/or developing into the wet
39 form be devised?
40

41 ***Cataract***

- 42
43
44 1. How can cataracts be prevented from developing?
45

46 ***Childhood-onset disorders***

- 47
48 1. How can cerebral visual impairment be identified, prevented and treated in
49 children?
50

51 ***Corneal and external diseases***

- 52
53
54 1. Can new therapies such as gene or stem cell treatments be developed for
55 corneal diseases?
56

57 ***Glaucoma***

1. What are the most effective treatments for glaucoma and how can treatment be improved?

Inherited retinal diseases

1. Can a treatment to slow down progression or reverse sight loss in inherited retinal diseases be developed?

Neuro-ophthalmology

1. What is the underlying cause of optic nerve damage in optic neuropathies, such as anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?

Ocular cancer

1. What can be done to help ocular cancer sufferers?

Ocular inflammatory diseases

1. What are the most effective treatments for ocular and orbital inflammatory diseases?

Refractive error and ocular motility

1. What factors influence the development of refractive error (myopia, astigmatism, presbyopia and long-sightedness)?

Retinal vascular diseases

1. What are the best methods to prevent retinopathy of prematurity?

Vitreoretinal and ocular trauma

1. How can surgical techniques be improved to save sight for eyes damaged by injury?

Discussion

About 50% of sight loss in the UK is currently avoidable¹. Recognising this and the UK's pre-eminent position in eye research, the Vision 2020UK ERG considered that any UK Research Agenda must look at addressing unavoidable sight loss for it to be credible. The challenge was to produce a coherently constructed and constituted prioritised research agenda whose methods were clear and for which there had been

1
2
3 inclusive and widespread consultation, where everyone with an interest had been
4 offered the opportunity to contribute and be heard. As a result of this priority setting
5 partnership we have established top ten lists of research questions for a range of
6 eye conditions.
7
8

9
10 There are a number of strengths to this study. The SLV-PSP is unique because it
11 sought the combined views of patients, carers and eye health professionals to
12 identify uncertainties about the prevention, diagnosis and treatment of sight loss and
13 eye conditions and prioritise them for research to address⁵. It is rare that those with
14 direct experience of conditions are able to influence the research agenda^{3,5,6}. The
15 views of patients, carers and professionals were given equal merit. All submitted
16 questions were evaluated independently and equally. Duplicate questions and out of
17 scope questions were removed. We did not encounter particularly
18 misunderstandings between lay persons and professionals or insufficient knowledge
19 of the public. Open discussions occurred during the face-to-face workshops with
20 good communication and facilitation to encourage respectful listening in accordance
21 with James Lind Alliance guidelines. Questions could only be pooled if this was
22 agreed by patients, carers and professionals. Where there was no agreement, the
23 questions remained separate. Thus, any differing perspectives of priorities between
24 participants were acknowledged. We did not aim to compare and contrast questions
25 from patients, carers and professionals but to represent and act on all.
26
27

28
29 This SLV-PSP provided an extensive set of unanswered questions prioritised by
30 patients, carers and eye health professionals across twelve categories of eye
31 conditions. These questions addressed a broad range of eye conditions and
32 considered issues of aetiology, prevention, screening, assessment and
33 management. Importantly, the public were as likely to propose questions in relation
34 to aetiology, assessment and management just as professionals were as likely to
35 raise questions regarding impact of sight loss.
36
37

38
39 In addition to the strengths of our study, we identified a number of limitations. We did
40 not request the views of 'pure' researchers (i.e. scientists with no current clinical
41 practice) as these individuals are intentionally excluded from the priority setting
42 process by the James Lind Alliance. This step is a key feature of the James Lind
43 Alliance methodology in which the remit is to provide an opportunity for patients,
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 carers and clinicians to influence the research agenda. We acknowledge this is a
4 different approach but do not consider their exclusion as a flaw in this process as we
5 include clinical researchers who did take part alongside clinicians and the public.
6
7

8
9 These questions may now be used to encourage researchers to investigate what is
10 most important to these groups. We do not know how our research questions
11 compare to the prioritisation of research areas by scientists, government agencies or
12 other organisation research funders. We are unaware of any systematic data
13 collating such data. However, similar to other PSP processes, we have provided
14 information on our research priorities openly to national funding organisations and it
15 is envisaged that research funders will be able to use the list to inform commissioned
16 calls for research and identify which research applications to response mode funding
17 opportunities can answer questions that these groups have agreed are a priority.
18 Furthermore, any questions or uncertainties not prioritised in this process were
19 submitted to and are currently available on the UK Database of Uncertainties about
20 the Effects of Treatments (UK DUETs). Thus individuals looking for uncertainties for
21 their research can access such information direct from UK DUETs. This sharing of
22 information contributes to the quality assurance process of avoiding waste in
23 research.
24
25
26
27
28
29
30
31
32

33
34 The SLV-PSP will also help to increase awareness of why research into sight loss
35 and vision is necessary and important. It will be used to campaign for major funders
36 to invest in sight loss and eye conditions, all of which are placing increased
37 emphasis on researchers demonstrating how they have consulted and involved the
38 public and patients in the process of developing their research.
39
40
41
42

43
44 These remain significant goals. For a sector with around 700 organisations to arrive
45 at any kind of consensus for research priority areas, a process that was genuinely
46 consultative, open and engaging to the individuals whose interests these
47 organisations represent as well as at an organisational level was recognised as
48 being critical. For a prioritisation exercise to be useful to the sector it needed to
49 make sense to funders and statutory bodies with responsibilities and interests in
50 these areas as well as to researchers. It was recognised that a prioritisation of
51 research areas produced by a small group within the sector would not be credible
52 and would never engage the support required for it to achieve the goals listed above.
53
54
55
56
57
58
59
60

Conclusions

Following a systematic process of national consultation and widespread survey of patients, carers and clinicians, 2220 individuals generated 4461 questions. Through a process of data analysis, interim prioritisation and final workshops, a top ten or eleven research questions have been identified for twelve categories of eye conditions. This is the first time, to our knowledge, that an exercise like this has been carried out anywhere in the world for sight loss and vision. Not only is this the most wide ranging and ambitious James Lind Alliance priority setting partnership, it also engaged a diversity of participants and enabled them to reach consensus together. For the first time, we have a clear idea of what the consumers of eye research – the patients and the people who care for and treat them – believe research money should be spent on. It has provided a focus for research in sight loss and vision and it is intended that these priorities are used to inform funders, researchers, clinicians and the public.

1
2
3 **Competing interests:** The authors declare that they have no competing interests.
4

5 **Funding:** This work was supported through funding and/or in-kind support by
6 College of Optometrists, Fight for Sight, James Lind Alliance, NIHR Moorfields BRC,
7 RNIB, Royal College of Ophthalmologists and UK Vision Strategy.
8
9

10 **Author contributions:** FR, RW, RC, MA, KB, MB, CBr, CBu, DC, KC, KE, MF, HG,
11 IG, LH, RH, AL, MV, HW and AZ contributed to the conduct of the survey. FR, RW,
12 RC, MA, MB, DC and KC were involved in the drafting of the paper. KB, CBr, CBu,
13 KE, MF, HG, IG, LH, RH, AL, MV, HW and AZ contributed to proofing of the paper.
14
15
16
17

18 **Data sharing statement:** All original data are held by Fight for Sight. Extra data is
19 available from: <http://www.library.nhs.uk/duets/SearchResults.aspx?catID=14501>
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Access Economics (2009) Future Sight Loss UK 1: The economic impact of partial sight and blindness in the UK adult population, RNIB
2. <http://www.vision2020uk.org.uk/>
3. Chalmers, I. and Glasziou, P. (2009) 'Avoidable waste in the production and reporting of research evidence', *The Lancet*, Vol. 374, pp. 86–89.
4. Sight loss and vision priority setting partnership. Setting priorities for eye research. (2013) Final report. www.sightlosspsp.org.uk
5. Stewart, R. and Oliver, S. (2008) *A systematic map of studies of patients' and clinicians' research priorities*. London: James Lind Alliance.
6. Caron-Flinterman J, et al. (2006) Patients priorities concerning health research: the case of asthma and COPD research in the Netherlands. *Health Expectations*, 8, pp253–263.

Table 1 Categories of eye condition

	Initial number of survey questions	Number of questions at interim prioritisation	Number of participants at interim prioritisation	Number of questions at final prioritisation
Age-related macular degeneration	763	43	101 PPI 25 Professionals	29
Cataract	191	27	Not required	27
Childhood-onset disorders	125	69	12 PPI 20 Professionals	30
Corneal and external diseases	292	93	25 PPI 38 Professionals	30
Glaucoma	1235	78	182 PPI 25 Professionals	30
Inherited retinal diseases	280	63	27 PPI 25 Professionals	30
Neuro-ophthalmology	125	43	15 PPI 21 Professionals	30
Ocular cancer	26	19	Not required	19
Ocular inflammatory diseases	472	66	27 PPI 21 Professionals	30

Refractive error and ocular motility	188	70	21 PPI 23 Professionals	31
Retinal vascular diseases	205	56	15 PPI 12 Professionals	30
Vitreoretinal and ocular trauma	265	59	21 PPI 8 Professionals	30

PPI: Inclusive of patients, carers, relatives, organisation representatives.

Professionals: Inclusive of eye health professions.

Table 2 Final workshop participants

Category	Total number of workshop participants	Number of patients, relatives, carers, patient groups and organisations	Number of eye health professionals
Age-related Macular Degeneration	17	9	8
Cataract	11	5	6
Childhood-Onset Disorders	16	7	9
Corneal and External Diseases	12	5	7
Glaucoma	17	9	8
Inherited Retinal Diseases	19	11	8
Neuro-ophthalmology	10	6	4
Ocular Cancer	10	6	4
Ocular Inflammatory Diseases	10	5	5
Refractive Error and Ocular Motility	12	5	7
Retinal Vascular Diseases	11	3	8
Vitreoretinal and Ocular Trauma	10	7	3
TOTAL	155	78	77

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 3 Top ten lists per category

	Age-related macular degeneration	Cataract	Childhood-onset disorders	Corneal and external diseases	Glaucoma	Inherited retinal diseases
1	Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised? What is the cause of AMD?	How can cataracts be prevented from developing?	How can cerebral visual impairment be identified, prevented and treated in children?	Can new therapies such as gene or stem cell treatments be developed for corneal diseases?	What are the most effective treatments for glaucoma and how can treatment be improved? How can loss of vision be restored for people with glaucoma?	Can a treatment to slow down progression or reverse sight loss in inherited retinal diseases be developed? How can sight loss be prevented in an individual with inherited retinal disease?
2	How can AMD be prevented?	Can the return of cloudy or blurred vision after cataract surgery known as posterior capsule opacity (PCO) or secondary cataract be prevented? How can cataract progression be slowed down?	How can treatment for visual pathway damage associated with pre-term birth be developed?	What is the most effective management for dry eye and can new strategies be developed?	How can glaucoma be stopped from progressing?	Is a genetic (molecular) diagnosis possible for all inherited retinal diseases?
3	Are there ways of restoring sight loss for people with AMD?	What alternatives to treat cataracts other than cataract surgery are being developed?	How do we improve screening and surveillance from the ante-natal period through to childhood to ensure early diagnosis of impaired vision and eye conditions?	Can treatments to save eye sight from microbial keratitis be improved?	What can be done to improve early diagnosis of sight-threatening glaucoma?	What factors affect the progression of sight loss in inherited retinal diseases?
4	Can the development of AMD be predicted?	What is the cause of cataract?	Can the treatment of amblyopia be improved to produce better short and long term outcomes than are possible with current treatments?	How can the rejection of corneal transplants be prevented?	What causes glaucoma?	What causes sight loss in inherited retinal diseases?
5	What is the most effective way to detect and monitor the progression of early AMD?	How can cataract surgery outcomes be improved?	How can cataract be prevented in children?	Can the outcomes of corneal transplantation be improved?	What is the most effective way of monitoring the progression of glaucoma?	What is the most effective way to support patients with inherited retinal disease?
6	What factors influence the progression of AMD?	How safe and effective is laser assisted cataract surgery?	What are the causes of coloboma and microphthalmia/anophthalmia and how can they be prevented?	Can non-surgical therapy be developed for Fuchs' corneal dystrophy?	How can glaucoma patients with a higher risk to progress rapidly be detected?	Can the diagnosis of inherited retinal diseases be refined so that individuals can be given a clearer idea about their specific condition and how it is likely to progress?
7	Can a non-invasive therapy be developed for wet AMD?	Should accommodative lenses be developed for cataract surgery?	Can vision be corrected in later life for people with amblyopia?	How can retinoblastoma be identified, prevented and treated in children?	Why is glaucoma more aggressive in people of certain ethnic groups, such as those of West African origin?	What is the relationship between sight loss and mental health for people with inherited retinal diseases?
8	Can dietary factors, nutritional supplements, complementary therapies or lifestyle changes prevent or slow the progression of AMD?	What is the best measure of visual disability due to cataract?	Can better treatments for glaucoma in children be developed?	What is the cause of keratoconus and can it be prevented?	How can glaucoma be prevented?	Would having a treatment for an inherited retinal disease preclude a patient from having another treatment?
9	What are the best enablement strategies for people with AMD?	Can retinal detachment be prevented after cataract surgery?	Can a treatment be developed to improve vision for people with albinism?	What is the most effective management of ocular complications associated with Stevens Johnson Syndrome?	Is there a link between treatment adherence and glaucoma progression and how can adherence be improved?	With regard to inherited retinal diseases what is the role of pre-natal and pre-implantation diagnosis in helping parents make informed choices?
10		What are the outcomes for cataract surgery among people with different levels of cognitive		Can severe ocular surface disease in children, such as blepharokeratoconjunctivitis and		

	<i>Neuro-ophthalmology</i>	<i>Ocular cancer</i>	<i>Ocular inflammatory diseases</i>	<i>Refractive error and ocular motility</i>	<i>Retinal vascular diseases</i>	<i>Vitreoretinal and ocular trauma</i>
1		impairment (all causes excluding dementia, stroke, neurological conditions, head injuries)?		vernal keratoconjunctivitis be managed better?		
2						
3						
4						
5						
6						
7						
8	1	What can be done to help ocular cancer sufferers?	What are the most effective treatments for ocular and orbital inflammatory diseases?	What factors influence the development of refractive error (myopia, astigmatism, presbyopia and long-sightedness)?	What are the best methods to prevent retinopathy of prematurity?	How can surgical techniques be improved to save sight for eyes damaged by injury?
9						
10						
11						
12						
13						
14	2	Can gene-based targeted therapies for ocular cancers be developed?	What causes thyroid eye disease?	What is the cause of both congenital and acquired nystagmus?	How can sight loss from diabetic retinal changes be prevented and reduced?	How can the risk of losing sight for people with retinal detachment be reduced?
15						
16						
17						
18						
19	3	How can immunotherapy be used to fight metastatic ocular melanoma?	Can the severity of ocular and orbital inflammatory disease in an individual be predicted?	How can the development of binocular vision in young children with squint and amblyopia be promoted, and would the same approach work in older individuals without inducing intractable diplopia?	What are the predictive factors for the progression to sight threatening diabetic eye disease?	How can better interventions be developed that are effective in treating vitreous opacities/eye floaters?
20						
21						
22						
23						
24						
25	4	What are the most effective detection and screening methods for follow up to detect metastasis of ocular melanoma?	Is it possible to prevent further occurrences of retinal damage caused by toxoplasmosis?	Would correction of refractive error have a positive impact on early life learning and development?	Is there a way to improve screening of premature babies for retinopathy of prematurity?	What causes retinal detachment and can it be prevented?
26						
27						
28						
29						
30						
31	5	How can follow-up for ocular complications be managed in patients with ocular melanoma?	What causes birdshot retinopathy?	Does early diagnosis of refractive error improve long-term prognosis and promote faster, more effective treatment?	Can an effective long lasting treatment for diabetic macular oedema, both ischaemic and non-ischaemic, be developed?	Can more effective diagnostic tools be developed for assessing the vitreous and eye floaters?
32						
33						
34						
35	6	What is the best management of metastatic choroidal melanoma?	Why does disease burn out in patients with ocular and orbital inflammatory diseases?	What is the effect of congenital nystagmus on visual and emotional development?	Can a retinal vein occlusion be predicted and prevented?	Can a functioning prosthetic eye be developed to replace an eye damaged by injury?
36						
37						
38	7	What activates choroidal melanoma metastasis in the liver after the primary melanoma has been treated?	Can early detection methods be developed for ocular and orbital inflammatory diseases?	What is the most effective treatment for exotropia and when should it be delivered?	Can new non-invasive treatments be developed to slow down the progression of diabetic retinopathy?	How can epiretinal membrane/fibrosis be prevented or treated?
39						
40						
41						
42						
43	8	Can adjuvant therapies be developed to treat ocular	What medications best prevent the development of eye disease in	How can the functional effects of surgical treatment for squint best	What are the barriers that prevent diabetic patients	Can stem cells be used to regrow an eye or part of an eye?
44						

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	motility manifestations following stroke?	melanoma?	Behcets?	be assessed?	having regular eye checks?	
9	How can electronic devices improve or restore vision for people with optic neuropathies?	What are the causes of ocular cancer and how can they be prevented?	What causes scleritis?	Could the accurate testing of refractive error be made less dependent on a subjective response i.e. the person's own response?	What rehabilitation programmes are best for the management of distorted vision from retinal diseases?	What causes posterior vitreous detachment/vitreous syneresis?
10	Can an alternative or new treatment be developed that will treat the sight loss caused by giant cell arteritis?	What is the most effective treatment for primary ocular melanoma?	Can diet or lifestyle changes prevent uveitis from developing?	How can myopia be prevented?	What is the efficacy and safety of anti-VEGF agents in the treatment of retinopathy of prematurity?	Are there methods to prevent and improve the treatment of macular holes?

For peer review only

Figure legends

Figure 1: Flowchart showing the steps of the process from Stage 1 when establishing the PSP through to Stage 5 at the final prioritisation.

Figure 2: Background of respondents showing that questions were largely received from people who have sight loss or an eye condition, but also including eye health professions, organisations, parents, family and carers.

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): Overview and results of the research prioritisation **survey process.**

Fiona Rowe¹, Richard Wormald^{2,3}, Richard Cable⁴, Michele Acton⁴, Karen Bonstein⁵, Michael Bowen⁶, Carol Bronze⁷, Catey Bunce^{2,3,5}, Dolores Conroy⁴, Katherine Cowan⁸, Kathy Evans⁹, Mark Fenton¹⁰, Heather Giles⁷, Iris Gordon³, Louise Halfhide⁵, Robert Harper¹¹, Anita Lightstone¹², Marcela Votruba¹³, Heather Waterman¹⁴, Antra Zekite²

1. British and Irish Orthoptic Society, London, UK
2. Department of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK
3. The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine, London, UK
4. Fight for Sight, London, UK
5. NIHR Moorfields Biomedical Research Centre for Ophthalmology, Institute of Ophthalmology, London, UK
6. College of Optometrists, London, UK
7. Patient representative
8. The James Lind Alliance (JLA) –National Institute for Health Research, Southampton, UK
9. Royal College of Ophthalmologists, London, UK
10. UK DUETs (NICE Evidence – UK Database of Uncertainties about the Effects of Treatments), London, UK
11. Department of Optometry, Manchester Royal Eye Hospital, Manchester, UK
12. UK Vision Strategy / VISION 2020 UK, London, UK
13. Department of Ophthalmology, Cardiff University, Cardiff, UK
14. Department of Nursing, University of Manchester, Manchester, UK

Corresponding author:

Dr Fiona Rowe

Department of Health Services Research,

1
2
3 WhelanBuilding (1.10),
4
5 University of Liverpool,
6
7
8 Brownlow Hill,
9
10 Liverpool L69 3GB
11
12
13 T: 0151 7944956
14
15 E: rowef@liverpool.ac.uk
16
17
18
19

20 **Word count:** 2573

21
22 **Number of figures:** 2

23
24
25 **Number of tables:** 3

26
27
28 **Short title:** Sight Loss and Vision Priority Setting Partnership

29
30 **Competing interests:** The authors declare that they have no competing interests.

31
32
33 **Funding:** This work was supported through funding and/or in-kind support by
34 College of Optometrists, Fight for Sight, James Lind Alliance, NIHR Moorfields BRC,
35 RNIB, Royal College of Ophthalmologists and UK Vision Strategy.
36
37

38
39 **Author contributions:** FR, RW, RC, MA, KB, MB, CBr, CBu, DC, KC, KE, MF, HG,
40 IG, LH, RH, AL, MV, HW and AZ contributed to the conduct of the survey. FR, RW,
41 RC, MA, MB, DC and KC were involved in the drafting of the paper. KB, CBr, CBu,
42 KE, MF, HG, IG, LH, RH, AL, MV, HW and AZ contributed to proofing of the paper.
43
44

45
46 **Data sharing statement:** All original data are held by Fight for Sight and James Lind
47 Alliance.
48

49 50 51 52 **Abstract**

53
54
55 Objectives: The Sight Loss and Vision Priority Setting Partnership aimed to identify
56 research priorities relating to sight loss and vision through consultation with patients,
57
58
59
60

carers and clinicians. These priorities can be used to inform funding bodies' decisions and enhance the case for additional research funding.

Design: Prospective survey with support from the James Lind Alliance.

Setting: UK wide NHS and non-NHS.

Participants: Patients, carers and eye health professionals. Academic researchers were excluded **solely from the prioritisation process**. The survey was disseminated by patient groups, professional bodies, at conferences and through the media, and was available for completion online, by phone, by post and by alternative formats (Braille and audio).

Outcome measure: People were asked to submit the questions about prevention, diagnosis and treatment of sight loss and eye conditions that they most wanted to see answered by research. Returned survey questions were reviewed by a data assessment group. **Priorities** were established across eye disease categories at final workshops.

Results: 2,220 people responded generating 4,461 submissions. Sixty-five percent of respondents had sight loss and/or an eye condition. Following initial data analysis, 686 submissions remained which were circulated for interim prioritisation (excluding cataract and ocular cancer questions) to 446 patients/carers and 218 professionals. The remaining 346 questions were discussed at final prioritisation workshops to reach agreement of top questions per category.

Conclusions: The exercise engaged a diverse community of stakeholders generating a wide range of conditions and research questions. Top priority questions were established across 12 eye disease categories.

Keywords: Sight loss; Vision; Research; Priorities; Partnership; James Lind Alliance

Article summary

Strengths and limitations of this study:

- Wide ranging and comprehensive coverage
- Substantial response

- The hardest to reach and those with the least opportunity to be heard may indeed have not been heard
- Any such groups now feeling excluded should have an opportunity to redress this.

Introduction

In the UK it is estimated that almost 2 million people are affected by sight loss and this number is expected to double by 2050¹. Currently 50% of sight loss in the UK is avoidable but there are also many unavoidable sight loss conditions. Whether it is to address childhood eye conditions or those affecting adults, research is needed to inform us about prevention, to develop new techniques for early diagnosis and to develop new and more effective treatments for many eye conditions.

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP) was developed from earlier work by the Eye Research Group (ERG) of VISION 2020 UK whose mission is the elimination of avoidable sight loss and the amelioration of the effects of sight loss when it cannot be avoided². The UK Vision Strategy sets out ways of addressing avoidable sight loss in the UK. There is much that can be done to improve the nation's eye health, and to eliminate avoidable sight loss. There are however gaps in the evidence base regarding eye health interventions and the best way to deliver services. Research is needed to support the UK Vision Strategy. In key areas research is urgently required to enable the Vision Strategy to be implemented in an evidence-based way that ensures efficient and effective development.

Despite on-going research in the UK and other countries, there are still many questions about the prevention, diagnosis and treatment of sight loss and eye conditions that remain unanswered. Given that resources for research are limited, it is important for research funders to understand how patients, carers and eye health professionals prioritise these unanswered questions so that future research can be consolidated and targeted accordingly³.

The purpose of this project was to undertake a comprehensive, UK-wide, survey of patients, carers and clinicians to identify research questions and priorities to inform decisions of funding bodies and enhance the case for additional research funding.

1
2
3 The priority setting process has been well established by the James Lind Alliance
4 (JLA) (<http://www.lindalliance.org/>) which has supported partnerships on a range of
5 topics since 2004. This partnership initiated by Fight for Sight, the UK's leading eye
6 research charity was established with support, financial and in kind, from the College
7 of Optometrists, the Royal College of Ophthalmologists, the NIHR Biomedical
8 Research Centre for Ophthalmology, the RNIB, UK Vision Strategy and the
9 Cochrane Eyes and Vision Group. A representative from the JLA convened meetings
10 of the steering committee and provided independent chairmanship for this and the
11 priority setting workshops. Their extensive experience in this process ensured no
12 single voice exerted undue influence over the prioritisation process and that the
13 views of patients, their carers and clinicians were paramount. The views of
14 researchers with no clinical involvement with patients and views of commercial
15 organisations were not included in the prioritisation.
16
17
18
19
20
21
22
23
24
25
26
27

28 **Methods and materials**

29
30 The detailed methods for this prioritisation process have been described in detail
31 elsewhere⁴. In brief, the process comprised five stages (figure 1). Our study did not
32 require ethical approval or consent from participants. James Lind Alliance priority
33 setting partnerships do not require ethical approval. Dissemination of the survey is
34 via open communications through professional bodies, charities and related
35 organisations. The survey is not undertaken through Higher Education Institutes or
36 through NHS organisations and does not recruit NHS patients. The survey contains
37 clear information on the aims of the priority setting partnership, how the process
38 works and how data will be used. In addition, submission of questions is
39 anonymised. For the workshops in which priorities were discussed and agreed,
40 participants choose to voluntarily attend and consent is not required for this. We
41 followed the ethical guidance for participation, information and evaluation from the
42 James Lind Alliance guidebook ([http://www.jlaguebook.org/jla-
43 guidebook.asp?val=56](http://www.jlaguebook.org/jla-guidebook.asp?val=56)).
44
45
46
47
48
49
50
51
52
53
54

55 ***Establishing the SLV-PSP***

1
2
3 A steering committee and data assessment group comprising the authors of this
4 article oversaw the process. Each member was responsible for contributing to and
5 managing a part of the process and was selected for their expertise and association
6 with eye research. The steering committee also included patient representatives
7 and eye health professionals. In April 2012 an initial stakeholder meeting was held to
8 engage the groups and organisations with member bases and community influence.
9 This was to ensure that the initial survey would be disseminated and completed by
10 as many patients, relatives, carers and eye health professionals as possible in the
11 UK.
12
13
14
15
16
17
18

19 ***Main survey***

20
21 The SLV-PSP survey was launched on 1 May 2012 and was open until 31 July 2012.
22 The aim of the survey was to identify patients', carers' and eye health professionals'
23 unanswered questions about sight loss and eye conditions. The survey's primary
24 question was "What question(s) about the prevention, diagnosis and treatment of
25 sight loss and eye conditions would you like to see answered by research?"
26
27
28
29

30 ***Data analysis***

31
32 Following closure of the survey, all submissions were examined. Out-of-scope
33 submissions were removed including those not related to the topic and uncertainties
34 better suited to social research. In-scope uncertainties were allocated into disease-
35 specific groups and re-worded in PICO format (Population, Intervention,
36 Comparison, Outcome). Searches were then undertaken to ascertain whether or not
37 each uncertainty could be answered by an up-to-date systematic review. All
38 unanswered uncertainties were then allocated to one of 12 eye disease categories,
39 with duplicates removed and similar questions combined. Checks were also made to
40 identify any on-going trials which might address the uncertainty. The 12 categories
41 were formed following discussions by the steering group on the most logical and
42 pragmatic way to organise the data within the time and resources available.
43
44
45
46
47
48
49
50
51

52 ***Interim prioritisation***

53
54 In order to start reducing the number of uncertainties, an interim prioritisation
55 exercise was conducted over email and by post. Patients, carers and eye health
56
57
58
59
60

professionals were invited to examine the long lists and then choose and rank 10 of the uncertainties.

Final prioritisation

The remaining uncertainties were ranked by patients, carers, relatives, organisation representatives and eye health professionals in one-day workshops facilitated by the JLA, using Nominal Group Technique – a mix of discussion and ranking. For each category, the top 10/11 questions were agreed.

Results

Main survey

In response to the survey, 2220 people generated 4461 submissions. Of these respondents, 17% identified themselves as healthcare professionals including primarily ophthalmologists, optometrists, orthoptists, ophthalmic nurses, opticians and people working in social care and rehabilitation (figure 2). Over 60% were people with sight loss or an eye condition. The average age of survey participants was 65.7 years old (range:16 months (proxy completion of survey by adult carer)to 105 years). Just under two thirds (62%) of respondents were female. The geographical split was: England 89%; Scotland 6%; Wales 4%; Northern Ireland 1%.

Data analysis

Following data analysis to remove duplicate/answered/out of scope uncertainties, 686 uncertainties remained. These were divided into twelve eye disease categories. Table 1 shows each category with the initial number of submissions received after the survey responses were submitted, the number of uncertainties sent to interim prioritisation, the number of participants at interim prioritisation and the number of uncertainties considered at the final prioritisation workshops.

Interim prioritisation

Respondents from the initial survey, organisations and eye healthcare professionals with expertise in the eye diseases in ten categories were contacted to provide interim priority rankings. The smaller number of questions asked in the categories relating to

1
2
3 cataract and ocular cancer meant that an interim prioritisation exercise was not
4 required for either category. A large response was received for the interim exercise,
5 with input from 446 patients, carers and relatives plus 218 eye health professionals.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Final prioritisation

In April and May 2013, 12 final prioritisation workshops were held: one for each eye disease category. Balanced numbers of patients/carers/relatives and eye health professionals participated. In total, 155 participants attended across all 12 workshops: 78 patients and 77 clinicians (table 2). The topics debated at each workshop comprised between 19-31 questions per category. Overall 153 questions about sight loss and vision were considered resulting in lists of 10/11 priorities for each of the 12 categories (table 3). The questions addressed the broad topics of aetiology, prevention, identification and interventions with the number 1 questions as follows:

Age-related macular degeneration

1. Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised?

Cataract

1. How can cataracts be prevented from developing?

Childhood-onset disorders

1. How can cerebral visual impairment be identified, prevented and treated in children?

Corneal and external diseases

1. Can new therapies such as gene or stem cell treatments be developed for corneal diseases?

Glaucoma

1. What are the most effective treatments for glaucoma and how can treatment be improved?

Inherited retinal diseases

1. Can a treatment to slow down progression or reverse sight loss in inherited retinal diseases be developed?

Neuro-ophthalmology

1. What is the underlying cause of optic nerve damage in optic neuropathies, such as anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?

Ocular cancer

1. What can be done to help ocular cancer sufferers?

Ocular inflammatory diseases

1. What are the most effective treatments for ocular and orbital inflammatory diseases?

Refractive error and ocular motility

1. What factors influence the development of refractive error (myopia, astigmatism, presbyopia and long-sightedness)?

Retinal vascular diseases

1. What are the best methods to prevent retinopathy of prematurity?

Vitreoretinal and ocular trauma

1. How can surgical techniques be improved to save sight for eyes damaged by injury?

Discussion

About 50% of sight loss in the UK is currently avoidable¹. Recognising this and the UK's pre-eminent position in eye research, the Vision 2020UK ERG considered that any UK Research Agenda must look at addressing unavoidable sight loss for it to be credible. The challenge was to produce a coherently constructed and constituted prioritised research agenda whose methods were clear and for which there had been inclusive and widespread consultation, where everyone with an interest had been offered the opportunity to contribute and be heard. **As a result of this priority setting partnership we have established top ten lists of research questions for a range of eye conditions.**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

There are a number of strengths to this study. The SLV-PSP is unique because it sought the combined views of patients, carers and eye health professionals to identify uncertainties about the prevention, diagnosis and treatment of sight loss and eye conditions and prioritise them for research to address⁵. It is rare that those with direct experience of conditions are able to influence the research agenda^{3,5,6}. The views of patients, carers and professionals were given equal merit. All submitted questions were evaluated independently and equally. Duplicate questions and out of scope questions were removed. We did not encounter particularly misunderstandings between lay persons and professionals or insufficient knowledge of the public. Open discussions occurred during the face-to-face workshops with good communication and facilitation to encourage respectful listening in accordance with James Lind Alliance guidelines. Questions could only be pooled if this was agreed by patients, carers and professionals. Where there was no agreement, the questions remained separate. Thus, any differing perspectives of priorities between participants were acknowledged. We did not aim to compare and contrast questions from patients, carers and professionals but to represent and act on all.

This SLV-PSP provided an extensive set of unanswered questions prioritised by patients, carers and eye health professionals across twelve categories of eye conditions. These questions addressed a broad range of eye conditions and considered issues of aetiology, prevention, screening, assessment and management. Importantly, the public were as likely to propose questions in relation to aetiology, assessment and management just as professionals were as likely to raise questions regarding impact of sight loss.

In addition to the strengths of our study, we identified a number of limitations. We did not request the views of 'pure' researchers (i.e. scientists with no current clinical practice) as these individuals are intentionally excluded from the priority setting process by the James Lind Alliance. This step is a key feature of the James Lind Alliance methodology in which the remit is to provide an opportunity for patients, carers and clinicians to influence the research agenda. We acknowledge this is a different approach but do not consider their exclusion as a flaw in this process as we include clinical researchers who did take part alongside clinicians and the public.

1
2
3 These questions may now be used to encourage researchers to investigate what is
4 most important to these groups. We do not know how our research questions
5 compare to the prioritisation of research areas by scientists, government agencies or
6 other organisation research funders. We are unaware of any systematic data
7 collating such data. However, similar to other PSP processes, we have provided
8 information on our research priorities openly to national funding organisations and it
9 is envisaged that research funders will be able to use the list to inform commissioned
10 calls for research and identify which research applications to response mode funding
11 opportunities can answer questions that these groups have agreed are a priority.
12 Furthermore, any questions or uncertainties not prioritised in this process were
13 submitted to and are currently available on the UK Database of Uncertainties about
14 the Effects of Treatments (UK DUETs). Thus individuals looking for uncertainties for
15 their research can access such information direct from UK DUETs. This sharing of
16 information contributes to the quality assurance process of avoiding waste in
17 research.
18
19
20
21
22
23
24
25
26
27

28
29 The SLV-PSP will also help to increase awareness of why research into sight loss
30 and vision is necessary and important. It will be used to campaign for major funders
31 to invest in sight loss and eye conditions, all of which are placing increased
32 emphasis on researchers demonstrating how they have consulted and involved the
33 public and patients in the process of developing their research.
34
35
36

37
38 These remain significant goals. For a sector with around 700 organisations to arrive
39 at any kind of consensus for research priority areas, a process that was genuinely
40 consultative, open and engaging to the individuals whose interests these
41 organisations represent as well as at an organisational level was recognised as
42 being critical. For a prioritisation exercise to be useful to the sector it needed to
43 make sense to funders and statutory bodies with responsibilities and interests in
44 these areas as well as to researchers. It was recognised that a prioritisation of
45 research areas produced by a small group within the sector would not be credible
46 and would never engage the support required for it to achieve the goals listed above.
47
48
49
50
51
52
53
54
55

56 Conclusions

57
58
59
60

1
2
3 Following a systematic process of national consultation and widespread survey of
4 patients, carers and clinicians, 2220 individuals generated 4461 questions. Through
5 a process of data analysis, interim prioritisation and final workshops, a top ten or
6 eleven research questions have been identified for twelve categories of eye
7 conditions. This is the first time, to our knowledge, that an exercise like this has been
8 carried out anywhere in the world for sight loss and vision. Not only is this the most
9 wide ranging and ambitious James Lind Alliance priority setting partnership, it also
10 engaged a diversity of participants and enabled them to reach consensus together.
11 For the first time, we have a clear idea of what the consumers of eye research – the
12 patients and the people who care for and treat them – believe research money
13 should be spent on. It has provided a focus for research in sight loss and vision and
14 it is intended that these priorities are used to inform funders, researchers, clinicians
15 and the public.
16
17
18
19
20
21
22
23
24
25
26
27

28 **Figure legends**

29
30 Figure 1: Flowchart showing the steps of the process from Stage 1 when
31 establishing the PSP through to Stage 5 at the final prioritisation.
32
33

34 Figure 2: Background of respondents showing that questions were largely received
35 from people who have sight loss or an eye condition, but also including eye health
36 professions, organisations, parents, family and carers.
37
38
39
40
41
42

43 **References**

- 44
45 1. Access Economics (2009) Future Sight Loss UK 1: The economic impact of
46 partial sight and blindness in the UK adult population, RNIB
- 47 2. <http://www.vision2020uk.org.uk/>
- 48 3. Chalmers, I. and Glasziou, P. (2009) 'Avoidable waste in the production and
49 reporting of research evidence', *The Lancet*, Vol. 374, pp. 86–89.
- 50 4. Sight loss and vision priority setting partnership. Setting priorities for eye
51 research. (2013) Final report. www.sightlosspsp.org.uk
52
53
54
55
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
5. Stewart, R. and Oliver, S. (2008) *A systematic map of studies of patients' and clinicians' research priorities*. London: James Lind Alliance.
6. Caron-Flinterman J, et al. (2006) Patients priorities concerning health research: the case of asthma and COPD research in the Netherlands. *Health Expectations*, 8, pp253–263.

For peer review only

Table 1 Categories of eye condition

	Initial number of survey questions	Number of questions at interim prioritisation	Number of participants at interim prioritisation	Number of questions at final prioritisation
Age-related macular degeneration	763	43	101 PPI 25 Professionals	29
Cataract	191	27	Not required	27
Childhood-onset disorders	125	69	12 PPI 20 Professionals	30
Corneal and external diseases	292	93	25 PPI 38 Professionals	30
Glaucoma	1235	78	182 PPI 25 Professionals	30
Inherited retinal diseases	280	63	27 PPI 25 Professionals	30
Neuro-ophthalmology	125	43	15 PPI 21 Professionals	30
Ocular cancer	26	19	Not required	19
Ocular inflammatory diseases	472	66	27 PPI 21 Professionals	30

Refractive error and ocular motility	188	70	21 PPI 23 Professionals	31
Retinal vascular diseases	205	56	15 PPI 12 Professionals	30
Vitreoretinal and ocular trauma	265	59	21 PPI 8 Professionals	30

PPI: Inclusive of patients, carers, relatives, organisation representatives.

Professionals: Inclusive of eye health professions.

Table 2 Final workshop participants

Category	Total number of workshop participants	Number of patients, relatives, carers, patient groups and organisations	Number of eye health professionals
Age-related Macular Degeneration	17	9	8
Cataract	11	5	6
Childhood-Onset Disorders	16	7	9
Corneal and External Diseases	12	5	7
Glaucoma	17	9	8
Inherited Retinal Diseases	19	11	8
Neuro-ophthalmology	10	6	4
Ocular Cancer	10	6	4
Ocular Inflammatory Diseases	10	5	5
Refractive Error and Ocular Motility	12	5	7
Retinal Vascular Diseases	11	3	8
Vitreoretinal and Ocular Trauma	10	7	3
TOTAL	155	78	77

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 3 Top ten lists per category

	Age-related macular degeneration	Cataract	Childhood-onset disorders	Corneal and external diseases	Glaucoma	Inherited retinal diseases
1	Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised? What is the cause of AMD?	How can cataracts be prevented from developing?	How can cerebral visual impairment be identified, prevented and treated in children?	Can new therapies such as gene or stem cell treatments be developed for corneal diseases?	What are the most effective treatments for glaucoma and how can treatment be improved? How can loss of vision be restored for people with glaucoma?	Can a treatment to slow down progression or reverse sight loss in inherited retinal diseases be developed? How can sight loss be prevented in an individual with inherited retinal disease?
2	How can AMD be prevented?	Can the return of cloudy or blurred vision after cataract surgery known as posterior capsule opacity (PCO) or secondary cataract be prevented? How can cataract progression be slowed down?	How can treatment for visual pathway damage associated with pre-term birth be developed?	What is the most effective management for dry eye and can new strategies be developed?	How can glaucoma be stopped from progressing?	Is a genetic (molecular) diagnosis possible for all inherited retinal diseases?
3	Are there ways of restoring sight loss for people with AMD?	What alternatives to treat cataracts other than cataract surgery are being developed?	How do we improve screening and surveillance from the ante-natal period through to childhood to ensure early diagnosis of impaired vision and eye conditions?	Can treatments to save eye sight from microbial keratitis be improved?	What can be done to improve early diagnosis of sight-threatening glaucoma?	What factors affect the progression of sight loss in inherited retinal diseases?
4	Can the development of AMD be predicted?	What is the cause of cataract?	Can the treatment of amblyopia be improved to produce better short and long term outcomes than are possible with current treatments?	How can the rejection of corneal transplants be prevented?	What causes glaucoma?	What causes sight loss in inherited retinal diseases?
5	What is the most effective way to detect and monitor the progression of early AMD?	How can cataract surgery outcomes be improved?	How can cataract be prevented in children?	Can the outcomes of corneal transplantation be improved?	What is the most effective way of monitoring the progression of glaucoma?	What is the most effective way to support patients with inherited retinal disease?
6	What factors influence the progression of AMD?	How safe and effective is laser assisted cataract surgery?	What are the causes of coloboma and microphthalmia/anophthalmia and how can they be prevented?	Can non-surgical therapy be developed for Fuchs' corneal dystrophy?	How can glaucoma patients with a higher risk to progress rapidly be detected?	Can the diagnosis of inherited retinal diseases be refined so that individuals can be given a clearer idea about their specific condition and how it is likely to progress?
7	Can a non-invasive therapy be developed for wet AMD?	Should accommodative lenses be developed for cataract surgery?	Can vision be corrected in later life for people with amblyopia?	Can corneal infections be prevented in high-risk individuals such as contact lens wearers?	Why is glaucoma more aggressive in people of certain ethnic groups, such as those of West African origin?	What is the relationship between sight loss and mental health for people with inherited retinal diseases?
8	Can dietary factors, nutritional supplements, complementary therapies or lifestyle changes prevent or slow the progression of AMD?	What is the best measure of visual disability due to cataract?	Can better treatments for glaucoma in children be developed?	What is the cause of keratoconus and can it be prevented?	How can glaucoma be prevented?	Would having a treatment for an inherited retinal disease preclude a patient from having another treatment?
9	What are the best enablement strategies for people with AMD?	Can retinal detachment be prevented after cataract surgery?	Can a treatment be developed to improve vision for people with albinism?	What is the most effective management of ocular complications associated with Stevens Johnson Syndrome?	Is there a link between treatment adherence and glaucoma progression and how can adherence be improved?	With regard to inherited retinal diseases what is the role of pre-natal and pre-implantation diagnosis in helping parents make informed choices?
10		What are the outcomes for cataract surgery among people with different levels of cognitive		Can severe ocular surface disease in children, such as blepharokeratoconjunctivitis and		


		impairment (all causes excluding dementia, stroke, neurological conditions, head injuries)?		vernal keratoconjunctivitis be managed better?		
	Neuro-ophthalmology	Ocular cancer	Ocular inflammatory diseases	Refractive error and ocular motility	Retinal vascular diseases	Vitreoretinal and ocular trauma
1	What is the underlying cause of optic nerve damage in optic neuropathies, such as anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?	What can be done to help ocular cancer sufferers?	What are the most effective treatments for ocular and orbital inflammatory diseases?	What factors influence the development of refractive error (myopia, astigmatism, presbyopia and long-sightedness)?	What are the best methods to prevent retinopathy of prematurity?	How can surgical techniques be improved to save sight for eyes damaged by injury?
2	What are the most effective treatments and rehabilitation for optic neuropathies, e.g. Leber's hereditary optic neuropathy and anterior ischaemic optic neuropathy?	Can gene-based targeted therapies for ocular cancers be developed?	What causes thyroid eye disease?	What is the cause of both congenital and acquired nystagmus?	How can sight loss from diabetic retinal changes be prevented and reduced?	How can the risk of losing sight for people with retinal detachment be reduced?
3	Can vision loss due to optic nerve diseases such as giant cell arteritis, Leber's hereditary optic neuropathy, optic neuritis and optic atrophy, be restored, for example through gene therapy and stem cell treatment?	How can immunotherapy be used to fight metastatic ocular melanoma?	Can the severity of ocular and orbital inflammatory disease in an individual be predicted?	How can the development of binocular vision in young children with squint and amblyopia be promoted, and would the same approach work in older individuals without inducing intractable diplopia?	What are the predictive factors for the progression to sight threatening diabetic eye disease?	How can better interventions be developed that are effective in treating vitreous opacities/eye floaters?
4	What rehabilitation or treatment methods are most effective for vision loss following brain damage due to stroke, brain injury, cerebral vision impairment, tumours and dementias?	What are the most effective detection and screening methods for follow up to detect metastasis of ocular melanoma?	Is it possible to prevent further occurrences of retinal damage caused by toxoplasmosis?	Would correction of refractive error have a positive impact on early life learning and development?	Is there a way to improve screening of premature babies for retinopathy of prematurity?	What causes retinal detachment and can it be prevented?
5	What is the most effective way to assess vision in patients with neurological visual impairment i.e. stroke, dementia and cerebral/cortical visual impairment?	How can follow-up for ocular complications be managed in patients with ocular melanoma?	What causes birdshot retinopathy?	Does early diagnosis of refractive error improve long-term prognosis and promote faster, more effective treatment?	Can an effective long lasting treatment for diabetic macular oedema, both ischaemic and non-ischaemic, be developed?	Can more effective diagnostic tools be developed for assessing the vitreous and eye floaters?
6	Can the early stages of optic neuropathy be detected?	What is the best management of metastatic choroidal melanoma?	Why does disease burn out in patients with ocular and orbital inflammatory diseases?	What is the effect of congenital nystagmus on visual and emotional development?	Can a retinal vein occlusion be predicted and prevented?	Can a functioning prosthetic eye be developed to replace an eye damaged by injury?
7	How can optic neuropathies be prevented, for example anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?	What activates choroidal melanoma metastasis in the liver after the primary melanoma has been treated?	Can early detection methods be developed for ocular and orbital inflammatory diseases?	What is the most effective treatment for exotropia and when should it be delivered?	Can new non-invasive treatments be developed to slow down the progression of diabetic retinopathy?	How can epiretinal membrane/fibrosis be prevented or treated?
8	Can treatments be developed for visual field and ocular	Can adjuvant therapies be developed to treat ocular	What medications best prevent the development of eye disease in	How can the functional effects of surgical treatment for squint best	What are the barriers that prevent diabetic patients	Can stem cells be used to regrow an eye or part of an eye?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

9	motility manifestations following stroke? How can electronic devices improve or restore vision for people with optic neuropathies?	melanoma? What are the causes of ocular cancer and how can they be prevented?	Behcets? What causes scleritis?	be assessed? Could the accurate testing of refractive error be made less dependent on a subjective response i.e. the person's own response? How can myopia be prevented?	having regular eye checks? What rehabilitation programmes are best for the management of distorted vision from retinal diseases? What is the efficacy and safety of anti-VEGF agents in the treatment of retinopathy of prematurity?	What causes posterior vitreous detachment/vitreous syneresis? Are there methods to prevent and improve the treatment of macular holes?
10	Can an alternative or new treatment be developed that will treat the sight loss caused by giant cell arteritis?	What is the most effective treatment for primary ocular melanoma?	Can diet or lifestyle changes prevent uveitis from developing?			

For peer review only


Figure 1 Flowchart of SLVPSP process



90x116mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



313x236mm (96 x 96 DPI)

ew only

BMJ Open

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): Overview and results of the research prioritisation survey process.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-004905.R2
Article Type:	Research
Date Submitted by the Author:	30-Jun-2014
Complete List of Authors:	Rowe, Fiona; University of Liverpool, Health Services Research Wormald, Richard; The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine, Eyes and Vision; Moorfields Eye Hospital NHS Foundation Trust, Ophthalmology Cable, Richard; Fight for Sight, Acton, Michele; Fight for Sight, Bonstein, Karen; Institute of Ophthalmology, NIHR Moorfields Biomedical Research Centre for Ophthalmology Bowen, Michael; College of Optometry, Bronze, Carol; Patient representative, Bunce, Catey; Moorfields Eye Hospital NHS Foundation Trust, Ophthalmology; Institute of Ophthalmology, NIHR Moorfields Biomedical Research Centre for Ophthalmology Conroy, Dolores; Fight for Sight, Cowan, Katherine; James Lind Alliance (JLA) –National Institute for Health Research, Evans, Kathy; Royal College of Ophthalmology, Fenton, Mark; UK DUETs (NICE Evidence – UK Database of Uncertainties about the Effects of Treatments), Giles, Heather; Patient representative, Gordon, Iris; The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine, Eyes and Vision Halfhide, Louise; Institute of Ophthalmology, NIHR Moorfields Biomedical Research Centre for Ophthalmology Harper, Robert; Manchester Royal Eye Hospital, Department of Optometry Lightstone, Anita; VISION 2020 UK, UK Vision Strategy Votruba, Marcela; Cardiff University, Department of Ophthalmology Waterman, Heather; University of Manchester, Department of Nursing Zekite, Antra; The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine, Eyes and Vision
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Ophthalmology, Qualitative research
Keywords:	Sight loss, Vision, Research, Priorities, Partnership, James Lind Alliance

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2014-004905 on 23 July 2014. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): Overview and results of the research prioritisation survey process.

Fiona Rowe¹, Richard Wormald^{2,3}, Richard Cable⁴, Michele Acton⁴, Karen Bonstein⁵, Michael Bowen⁶, Carol Bronze⁷, Catey Bunce^{2,3,5}, Dolores Conroy⁴, Katherine Cowan⁸, Kathy Evans⁹, Mark Fenton¹⁰, Heather Giles⁷, Iris Gordon³, Louise Halfhide⁵, Robert Harper¹¹, Anita Lightstone¹², Marcela Votruba¹³, Heather Waterman¹⁴, Antra Zekite²

1. British and Irish Orthoptic Society, London, UK
2. Department of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK
3. The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine, London, UK
4. Fight for Sight, London, UK
5. NIHR Biomedical Research Centre at Moorfields and UCL Institute of Ophthalmology, London, UK
6. College of Optometrists, London, UK
7. Patient representative
8. The James Lind Alliance (JLA) –National Institute for Health Research, Southampton, UK
9. Royal College of Ophthalmologists, London, UK
10. UK DUETs (NICE Evidence – UK Database of Uncertainties about the Effects of Treatments), London, UK
11. Department of Optometry, Manchester Royal Eye Hospital, Manchester, UK
12. UK Vision Strategy / VISION 2020 UK, London, UK
13. Department of Ophthalmology, Cardiff University, Cardiff, UK
14. Department of Nursing, University of Manchester, Manchester, UK

Corresponding author:

Dr Fiona Rowe

Department of Health Services Research,

1
2
3 WhelanBuilding (1.10),
4

5 University of Liverpool,
6

7 Brownlow Hill,
8

9
10 Liverpool L69 3GB
11

12
13 T: 0151 7944956
14

15 E: rowef@liverpool.ac.uk
16
17

18
19
20 **Word count:** 2573
21

22
23 **Number of figures:** 2
24

25
26 **Number of tables:** 3
27

28 **Short title:** Sight Loss and Vision Priority Setting Partnership
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: The Sight Loss and Vision Priority Setting Partnership aimed to identify research priorities relating to sight loss and vision through consultation with patients, carers and clinicians. These priorities can be used to inform funding bodies' decisions and enhance the case for additional research funding.

Design: Prospective survey with support from the James Lind Alliance.

Setting: UK wide NHS and non-NHS.

Participants: Patients, carers and eye health professionals. Academic researchers were excluded solely from the prioritisation process. The survey was disseminated by patient groups, professional bodies, at conferences and through the media, and was available for completion online, by phone, by post and by alternative formats (Braille and audio).

Outcome measure: People were asked to submit the questions about prevention, diagnosis and treatment of sight loss and eye conditions that they most wanted to see answered by research. Returned survey questions were reviewed by a data assessment group. Priorities were established across eye disease categories at final workshops.

Results: 2,220 people responded generating 4,461 submissions. Sixty-five percent of respondents had sight loss and/or an eye condition. Following initial data analysis, 686 submissions remained which were circulated for interim prioritisation (excluding cataract and ocular cancer questions) to 446 patients/carers and 218 professionals. The remaining 346 questions were discussed at final prioritisation workshops to reach agreement of top questions per category.

Conclusions: The exercise engaged a diverse community of stakeholders generating a wide range of conditions and research questions. Top priority questions were established across 12 eye disease categories.

Keywords: Sight loss; Vision; Research; Priorities; Partnership; James Lind Alliance

Article summary

Strengths and limitations of this study:

- Wide ranging and comprehensive coverage
- Substantial response
- The hardest to reach and those with the least opportunity to be heard may indeed have not been heard
- Any such groups now feeling excluded should have an opportunity to redress this.

Introduction

In the UK it is estimated that almost 2 million people are affected by sight loss and this number is expected to double by 2050¹. Currently 50% of sight loss in the UK is avoidable but there are also many unavoidable sight loss conditions. Whether it is to address childhood eye conditions or those affecting adults, research is needed to inform us about prevention, to develop new techniques for early diagnosis and to develop new and more effective treatments for many eye conditions.

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP) was developed from earlier work by the Eye Research Group (ERG) of VISION 2020 UK whose mission is the elimination of avoidable sight loss and the amelioration of the effects of sight loss when it cannot be avoided². The UK Vision Strategy sets out ways of addressing avoidable sight loss in the UK. There is much that can be done to improve the nation's eye health, and to eliminate avoidable sight loss. There are however gaps in the evidence base regarding eye health interventions and the best way to deliver services. Research is needed to support the UK Vision Strategy. In key areas research is urgently required to enable the Vision Strategy to be implemented in an evidence-based way that ensures efficient and effective development.

Despite on-going research in the UK and other countries, there are still many questions about the prevention, diagnosis and treatment of sight loss and eye conditions that remain unanswered. Given that resources for research are limited, it is important for research funders to understand how patients, carers and eye health professionals prioritise these unanswered questions so that future research can be consolidated and targeted accordingly³.

The purpose of this project was to undertake a comprehensive, UK-wide, survey of patients, carers and clinicians to identify research questions and priorities to inform decisions of funding bodies and enhance the case for additional research funding.

The priority setting process has been well established by the James Lind Alliance (JLA) (<http://www.lindalliance.org/>) which has supported partnerships on a range of topics since 2004. This partnership initiated by Fight for Sight, the UK's leading eye

1
2
3 research charity was established with support, financial and in kind, from the College
4 of Optometrists, the Royal College of Ophthalmologists, the NIHR Moorfields
5 Biomedical Research Centre, the RNIB, UK Vision Strategy and the Cochrane Eyes
6 and Vision Group. A representative from the JLA convened meetings of the steering
7 committee and provided independent chairmanship for this and the priority setting
8 workshops. Their extensive experience in this process ensured no single voice
9 exerted undue influence over the prioritisation process and that the views of patients,
10 their carers and clinicians were paramount. The views of researchers with no clinical
11 involvement with patients and views of commercial organisations were not included
12 in the prioritisation.
13
14
15
16
17
18
19
20
21
22

23 **Methods and materials**

24
25 The detailed methods for this prioritisation process have been described in detail
26 elsewhere⁴. In brief, the process comprised five stages (figure 1). Our study did not
27 require ethical approval or consent from participants. James Lind Alliance priority
28 setting partnerships do not require ethical approval. Dissemination of the survey was
29 via open communications through professional bodies, charities and related
30 organisations. The survey was not undertaken through Higher Education Institutes or
31 through NHS organisations and does not recruit NHS patients. The survey contained
32 clear information on the aims of the priority setting partnership, how the process
33 works and how data will be used. In addition, submission of questions was
34 anonymised. For the workshops in which priorities were discussed and agreed,
35 participants choose to voluntarily attend and consent was not required for this. We
36 followed the ethical guidance for participation, information and evaluation from the
37 James Lind Alliance guidebook ([http://www.jla-guidebook.org/jla-
38 guidebook.asp?val=56](http://www.jla-guidebook.org/jla-guidebook.asp?val=56)).
39
40
41
42
43
44
45
46
47
48

49 ***Establishing the SLV-PSP***

50
51 A steering committee and data assessment group comprising the authors of this
52 article oversaw the process. Each member was responsible for contributing to and
53 managing a part of the process and was selected for their expertise and association
54 with eye research. The steering committee also included patient representatives
55
56
57
58
59
60

1
2
3 and eye health professionals. In April 2012 an initial stakeholder meeting was held to
4 engage the groups and organisations with member bases and community influence.
5 This was to ensure that the initial survey would be disseminated and completed by
6 as many patients, relatives, carers and eye health professionals as possible in the
7 UK.
8
9
10

11 ***Main survey***

12 The SLV-PSP survey was launched on 1 May 2012 and was open until 31 July 2012.
13 The aim of the survey was to identify patients', carers' and eye health professionals'
14 unanswered questions about sight loss and eye conditions. The survey's primary
15 question was "What question(s) about the prevention, diagnosis and treatment of
16 sight loss and eye conditions would you like to see answered by research?"
17
18
19
20
21
22

23 ***Data analysis***

24 Following closure of the survey, all submissions were examined. Out-of-scope
25 submissions were removed including those not related to the topic and uncertainties
26 better suited to social research. In-scope uncertainties were allocated into disease-
27 specific groups and re-worded in PICO format (Population, Intervention,
28 Comparison, Outcome). Searches were then undertaken to ascertain whether or not
29 each uncertainty could be answered by an up-to-date systematic review. All
30 unanswered uncertainties were then allocated to one of 12 eye disease categories,
31 with duplicates removed and similar questions combined. Checks were also made to
32 identify any on-going trials which might address the uncertainty. The 12 categories
33 were formed following discussions by the steering group on the most logical and
34 pragmatic way to organise the data within the time and resources available.
35
36
37
38
39
40
41
42
43
44

45 ***Interim prioritisation***

46 In order to start reducing the number of uncertainties, an interim prioritisation
47 exercise was conducted over email and by post. Patients, carers and eye health
48 professionals were invited to examine the long lists and then choose and rank 10 of
49 the uncertainties.
50
51
52
53
54

55 ***Final prioritisation***

1
2
3 The remaining uncertainties were ranked by patients, carers, relatives, organisation
4 representatives and eye health professionals in one-day workshops facilitated by the
5 JLA, using Nominal Group Technique – a mix of discussion and ranking. For each
6 category, the top 10/11 questions were agreed.
7
8
9

10 11 12 13 **Results**

14 ***Main survey***

15
16
17 In response to the survey, 2220 people generated 4461 submissions. Of these
18 respondents, 17% identified themselves as healthcare professionals including
19 primarily ophthalmologists, optometrists, orthoptists, ophthalmic nurses, opticians
20 and people working in social care and rehabilitation (figure 2). Over 60% were
21 people with sight loss or an eye condition. The average age of survey participants
22 was 65.7 years old (range:16 months (proxy completion of survey by adult carer)to
23 105 years). Just under two thirds (62%) of respondents were female. The
24 geographical split was: England 89%; Scotland 6%; Wales 4%; Northern Ireland 1%.
25
26
27
28
29
30
31

32 ***Data analysis***

33
34 Following data analysis to remove duplicate/answered/out of scope uncertainties,
35 686 uncertainties remained. These were divided into twelve eye disease categories.
36 Table 1 shows each category with the initial number of submissions received after
37 the survey responses were submitted, the number of uncertainties sent to interim
38 prioritisation, the number of participants at interim prioritisation and the number of
39 uncertainties considered at the final prioritisation workshops.
40
41
42
43
44

45 ***Interim prioritisation***

46
47 Respondents from the initial survey, organisations and eye healthcare professionals
48 with expertise in the eye diseases in ten categories were contacted to provide interim
49 priority rankings. The smaller number of questions asked in the categories relating to
50 cataract and ocular cancer meant that an interim prioritisation exercise was not
51 required for either category. A large response was received for the interim exercise,
52 with input from 446 patients, carers and relatives plus 218 eye health professionals.
53
54
55
56
57
58
59
60

Uncertainties accumulated scores based on rank and frequency, resulting in short lists of around 30 uncertainties per category which were taken to final workshops.

Final prioritisation

In April and May 2013, 12 final prioritisation workshops were held: one for each eye disease category. Balanced numbers of patients/carers/relatives and eye health professionals participated. In total, 155 participants attended across all 12 workshops: 78 patients and 77 clinicians (table 2). The topics debated at each workshop comprised between 19-31 questions per category. Overall 153 questions about sight loss and vision were considered resulting in lists of 10/11 priorities for each of the 12 categories (table 3). The questions addressed the broad topics of aetiology, prevention, identification and interventions with the number 1 questions as follows:

Age-related macular degeneration

1. Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised?

Cataract

1. How can cataracts be prevented from developing?

Childhood-onset disorders

1. How can cerebral visual impairment be identified, prevented and treated in children?

Corneal and external diseases

1. Can new therapies such as gene or stem cell treatments be developed for corneal diseases?

Glaucoma

1. What are the most effective treatments for glaucoma and how can treatment be improved?

Inherited retinal diseases

1. Can a treatment to slow down progression or reverse sight loss in inherited retinal diseases be developed?

Neuro-ophthalmology

1. What is the underlying cause of optic nerve damage in optic neuropathies, such as anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?

Ocular cancer

1. What can be done to help ocular cancer sufferers?

Ocular inflammatory diseases

1. What are the most effective treatments for ocular and orbital inflammatory diseases?

Refractive error and ocular motility

1. What factors influence the development of refractive error (myopia, astigmatism, presbyopia and long-sightedness)?

Retinal vascular diseases

1. What are the best methods to prevent retinopathy of prematurity?

Vitreoretinal and ocular trauma

1. How can surgical techniques be improved to save sight for eyes damaged by injury?

Discussion

About 50% of sight loss in the UK is currently avoidable¹. Recognising this and the UK's pre-eminent position in eye research, the Vision 2020UK ERG considered that any UK Research Agenda must look at addressing unavoidable sight loss for it to be credible. The challenge was to produce a coherently constructed and constituted prioritised research agenda whose methods were clear and for which there had been inclusive and widespread consultation, where everyone with an interest had been offered the opportunity to contribute and be heard. As a result of this priority setting partnership we have established top ten lists of research questions for a range of eye conditions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

There are a number of strengths to this study. The SLV-PSP is unique because it sought the combined views of patients, carers and eye health professionals to identify uncertainties about the prevention, diagnosis and treatment of sight loss and eye conditions and prioritise them for research to address⁵. It is rare that those with direct experience of conditions are able to influence the research agenda^{3,5,6}. The views of patients, carers and professionals were given equal merit. All submitted questions were evaluated independently and equally. Duplicate questions and out of scope questions were removed. We did not encounter particular misunderstandings between lay persons and professionals or insufficient knowledge of the public. Open discussions occurred during the face-to-face workshops with good communication and facilitation to encourage respectful listening in accordance with James Lind Alliance guidelines. Questions could only be pooled if this was agreed by patients, carers and professionals. Where there was no agreement, the questions remained separate. Thus, any differing perspectives of priorities between participants were acknowledged. We did not aim to compare and contrast questions from patients, carers and professionals but to represent and act on all.

This SLV-PSP provided an extensive set of unanswered questions prioritised by patients, carers and eye health professionals across twelve categories of eye conditions. These questions addressed a broad range of eye conditions and considered issues of aetiology, prevention, screening, assessment and management. Importantly, the public were as likely to propose questions in relation to aetiology, assessment and management just as professionals were as likely to raise questions regarding impact of sight loss.

In addition to the strengths of our study, we identified a number of limitations. We were unable to calculate a response rate for the survey because of the nature of its design and implementation. We did not request the views of 'pure' researchers (i.e. scientists with no current clinical practice) as these individuals are intentionally excluded from the priority setting process by the James Lind Alliance. This step is a key feature of the James Lind Alliance methodology in which the remit is to provide an opportunity for patients, carers and clinicians to influence the research agenda. We acknowledge this is a different approach but do not consider their exclusion as a flaw in this process as we include clinical researchers who did take part alongside clinicians and the public.

1
2
3 These questions may now be used to encourage researchers to investigate what is
4 most important to these groups. We do not know how our research questions
5 compare to the prioritisation of research areas by scientists, government agencies or
6 other organisation research funders. We are unaware of any systematic data
7 collating such data.
8

9
10 Various organisations in the sector have set out priorities for eye health and eye
11 research in the past, for example Vision2020UK⁷. In addition, organisations
12 representing the interests of patients/carers and eye health professionals took part in
13 the process, both in promoting the survey and being directly involved in priority
14 setting. Future work to review the SLV-PSP projects priorities with these
15 organisations could be helpful in developing an understanding of how these new,
16 patient and clinician led priorities can inform the sectors approach to commissioning
17 research and focusing resources. Organisations in the sector are already working to
18 review their organisational priorities with the SLV priorities, and have begun to invite
19 researchers seeking funding to consider how their proposed research relates to the
20 SLV priorities.
21

22
23 Similar to other PSP processes, we have provided information on our research
24 priorities openly to national funding organisations and it is envisaged that research
25 funders will be able to use the list to inform commissioned calls for research and
26 identify which research applications to response mode funding opportunities can
27 answer questions that these groups have agreed are a priority. Furthermore, any
28 questions or uncertainties not prioritised in this process were submitted to and are
29 currently available on the UK Database of Uncertainties about the Effects of
30 Treatments (UK DUETs). Thus individuals looking for uncertainties for their research
31 can access such information direct from UK DUETs. This sharing of information
32 contributes to the quality assurance process of avoiding waste in research.
33

34
35 The SLV-PSP will also help to increase awareness of why research into sight loss
36 and vision is necessary and important. It will be used to campaign for major funders
37 to invest in sight loss and eye conditions, all of which are placing increased
38 emphasis on researchers demonstrating how they have consulted and involved the
39 public and patients in the process of developing their research.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 These remain significant goals. For a sector with around 700 organisations to arrive
4 at any kind of consensus for research priority areas, a process that was genuinely
5 consultative, open and engaging to the individuals whose interests these
6 organisations represent as well as at an organisational level was recognised as
7 being critical. For a prioritisation exercise to be useful to the sector it needed to
8 make sense to funders and statutory bodies with responsibilities and interests in
9 these areas as well as to researchers. It was recognised that a prioritisation of
10 research areas produced by a small group within the sector would not be credible
11 and would never engage the support required for it to achieve the goals listed above.
12
13
14
15
16
17
18
19
20

21 **Conclusions**

22
23 Following a systematic process of national consultation and widespread survey of
24 patients, carers and clinicians, 2220 individuals generated 4461 questions. Through
25 a process of data analysis, interim prioritisation and final workshops, a top ten or
26 eleven research questions have been identified for twelve categories of eye
27 conditions. This is the first time, to our knowledge, that an exercise like this has been
28 carried out anywhere in the world for sight loss and vision. Not only is this the most
29 wide ranging and ambitious James Lind Alliance priority setting partnership, it also
30 engaged a diversity of participants and enabled them to reach consensus together.
31 For the first time, we have a clear idea of what the consumers of eye research – the
32 patients and the people who care for and treat them – believe research money
33 should be spent on. It has provided a focus for research in sight loss and vision and
34 it is intended that these priorities are used to inform funders, researchers, clinicians
35 and the public.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Competing interests:** The authors declare that they have no competing interests.
4

5 **Funding:** This work was supported through funding and/or in-kind support by
6 College of Optometrists, Fight for Sight, James Lind Alliance, NIHR Moorfields BRC,
7 RNIB, Royal College of Ophthalmologists and UK Vision Strategy.
8
9

10 **Author contributions:** FR, RW, RC, MA, KB, MB, CBr, CBu, DC, KC, KE, MF, HG,
11 IG, LH, RH, AL, MV, HW and AZ contributed to the conduct of the survey. FR, RW,
12 RC, MA, MB, DC and KC were involved in the drafting of the paper. KB, CBr, CBu,
13 KE, MF, HG, IG, LH, RH, AL, MV, HW and AZ contributed to proofing of the paper.
14
15
16
17

18 **Data sharing statement:** All original data are held by Fight for Sight. Extra data is
19 available from: <http://www.library.nhs.uk/duets/SearchResults.aspx?catID=14501>
20 The additional unpublished data includes research questions not included in the final
21 top ten lists of research priorities.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Access Economics (2009) Future Sight Loss UK 1: The economic impact of partial sight and blindness in the UK adult population, RNIB
2. <http://www.vision2020uk.org.uk/>
3. Chalmers, I. and Glasziou, P. (2009) 'Avoidable waste in the production and reporting of research evidence', *The Lancet*, Vol. 374, pp. 86–89.
4. Sight loss and vision priority setting partnership. Setting priorities for eye research. (2013) Final report. www.sightlosspsp.org.uk
5. Stewart, R. and Oliver, S. (2008) *A systematic map of studies of patients' and clinicians' research priorities*. London: James Lind Alliance.
6. Caron-Flinterman J, et al. (2006) Patients priorities concerning health research: the case of asthma and COPD research in the Netherlands. *Health Expectations*, 8, pp253–263.
7. UK Vision Strategy 2013-2018. www.vision2020uk.org.uk

Table 1 Categories of eye condition

	Initial number of survey questions	Number of questions at interim prioritisation	Number of participants at interim prioritisation	Number of questions at final prioritisation
Age-related macular degeneration	763	43	101 PPI 25 Professionals	29
Cataract	191	27	Not required	27
Childhood-onset disorders	125	69	12 PPI 20 Professionals	30
Corneal and external diseases	292	93	25 PPI 38 Professionals	30
Glaucoma	1235	78	182 PPI 25 Professionals	30
Inherited retinal diseases	280	63	27 PPI 25 Professionals	30
Neuro-ophthalmology	125	43	15 PPI 21 Professionals	30
Ocular cancer	26	19	Not required	19

Ocular inflammatory diseases	472	66	27 PPI 21 Professionals	30
Refractive error and ocular motility	188	70	21 PPI 23 Professionals	31
Retinal vascular diseases	205	56	15 PPI 12 Professionals	30
Vitreoretinal and ocular trauma	265	59	21 PPI 8 Professionals	30

PPI: Inclusive of patients, carers, relatives, organisation representatives.

Professionals: Inclusive of eye health professions.

Table 2 Final workshop participants

Category	Total number of workshop participants	Number of patients, relatives, carers, patient groups and organisations	Number of eye health professionals
Age-related Macular Degeneration	17	9	8
Cataract	11	5	6
Childhood-Onset Disorders	16	7	9
Corneal and External Diseases	12	5	7
Glaucoma	17	9	8
Inherited Retinal Diseases	19	11	8
Neuro-ophthalmology	10	6	4
Ocular Cancer	10	6	4
Ocular Inflammatory Diseases	10	5	5
Refractive Error and Ocular Motility	12	5	7
Retinal Vascular Diseases	11	3	8
Vitreoretinal and Ocular Trauma	10	7	3
TOTAL	155	78	77

Table 3 Top ten lists per category

	Age-related macular degeneration	Cataract	Childhood-onset disorders	Corneal and external diseases	Glaucoma	Inherited retinal diseases
1	Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised?	How can cataracts be prevented from developing?	How can cerebral visual impairment be identified, prevented and treated in children?	Can new therapies such as gene or stem cell treatments be developed for corneal diseases?	What are the most effective treatments for glaucoma and how can treatment be improved?	Can a treatment to slow down progression or reverse sight loss in inherited retinal diseases be developed?
2	What is the cause of AMD?	Can the return of cloudy or blurred vision after cataract surgery known as posterior capsule opacity (PCO) or secondary cataract be prevented?	How can treatment for visual pathway damage associated with pre-term birth be developed?	What is the most effective management for dry eye and can new strategies be developed?	How can loss of vision be restored for people with glaucoma?	How can sight loss be prevented in an individual with inherited retinal disease?
3	How can AMD be prevented?	How can cataract progression be slowed down?	How do we improve screening and surveillance from the ante-natal period through to childhood to ensure early diagnosis of impaired vision and eye conditions?	Can treatments to save eye sight from microbial keratitis be improved?	How can glaucoma be stopped from progressing?	Is a genetic (molecular) diagnosis possible for all inherited retinal diseases?
4	Are there ways of restoring sight loss for people with AMD?	What alternatives to treat cataracts other than cataract surgery are being developed?	Can the treatment of amblyopia be improved to produce better short and long term outcomes than are possible with current treatments?	How can the rejection of corneal transplants be prevented?	What can be done to improve early diagnosis of sight-threatening glaucoma?	What factors affect the progression of sight loss in inherited retinal diseases?
5	Can the development of AMD be predicted?	What is the cause of cataract?	How can cataract be prevented in children?	Can the outcomes of corneal transplantation be improved?	What causes glaucoma?	What causes sight loss in inherited retinal diseases?
6	What is the most effective way to detect and monitor the progression of early AMD?	How can cataract surgery outcomes be improved?	What are the causes of coloboma and microphthalmia/anophthalmia and how can they be prevented?	What causes keratoconus to progress and can progression be prevented?	What is the most effective way of monitoring the progression of glaucoma?	What is the most effective way to support patients with inherited retinal disease?
7	What factors influence the progression of AMD?	How safe and effective is laser assisted cataract surgery?	Can vision be corrected in later life for people with amblyopia?	Can non-surgical therapy be developed for Fuchs' corneal dystrophy?	How can glaucoma patients with a higher risk to progress rapidly be detected?	Can the diagnosis of inherited retinal diseases be refined so that individuals can be given a clearer idea about their specific condition and how it is likely to progress?
8	Can a non-invasive therapy be developed for wet AMD?	Should accommodative lenses be developed for cataract surgery?	How can retinoblastoma be identified, prevented and treated in children?	Can corneal infections be prevented in high-risk individuals such as contact lens wearers?	Why is glaucoma more aggressive in people of certain ethnic groups, such as those of West African origin?	What is the relationship between sight loss and mental health for people with inherited retinal diseases?
9	Can dietary factors, nutritional supplements, complementary therapies or lifestyle changes prevent or slow the progression of AMD?	What is the best measure of visual disability due to cataract?	Can better treatments for glaucoma in children be developed?	What is the cause of keratoconus and can it be prevented?	How can glaucoma be prevented?	Would having a treatment for an inherited retinal disease preclude a patient from having another treatment?
10	What are the best enablement strategies for people with AMD?	Can retinal detachment be prevented after cataract surgery?	Can a treatment be developed to improve vision for people with albinism?	What is the most effective management of ocular complications associated with Stevens Johnson Syndrome?	Is there a link between treatment adherence and glaucoma progression and how can adherence be improved?	With regard to inherited retinal diseases what is the role of pre-natal and pre-implantation diagnosis in helping parents make informed choices?
11		What are the outcomes for cataract surgery among people with different levels of cognitive		Can severe ocular surface disease in children, such as blepharokeratoconjunctivitis and		

	Neuro-ophthalmology	Ocular cancer	Ocular inflammatory diseases	Refractive error and ocular motility	Retinal vascular diseases	Vitreoretinal and ocular trauma	
1		impairment (all causes excluding dementia, stroke, neurological conditions, head injuries)?		vernal keratoconjunctivitis be managed better?			
2							
3							
4							
5							
6							
7							
8	1	What is the underlying cause of optic nerve damage in optic neuropathies, such as anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?	What can be done to help ocular cancer sufferers?	What are the most effective treatments for ocular and orbital inflammatory diseases?	What factors influence the development of refractive error (myopia, astigmatism, presbyopia and long-sightedness)?	What are the best methods to prevent retinopathy of prematurity?	How can surgical techniques be improved to save sight for eyes damaged by injury?
9							
10							
11							
12							
13							
14	2	What are the most effective treatments and rehabilitation for optic neuropathies, e.g. Leber's hereditary optic neuropathy and anterior ischaemic optic neuropathy?	Can gene-based targeted therapies for ocular cancers be developed?	What causes thyroid eye disease?	What is the cause of both congenital and acquired nystagmus?	How can sight loss from diabetic retinal changes be prevented and reduced?	How can the risk of losing sight for people with retinal detachment be reduced?
15							
16							
17							
18							
19	3	Can vision loss due to optic nerve diseases such as giant cell arteritis, Leber's hereditary optic neuropathy, optic neuritis and optic atrophy, be restored, for example through gene therapy and stem cell treatment?	How can immunotherapy be used to fight metastatic ocular melanoma?	Can the severity of ocular and orbital inflammatory disease in an individual be predicted?	How can the development of binocular vision in young children with squint and amblyopia be promoted, and would the same approach work in older individuals without inducing intractable diplopia?	What are the predictive factors for the progression to sight threatening diabetic eye disease?	How can better interventions be developed that are effective in treating vitreous opacities/eye floaters?
20							
21							
22							
23							
24							
25	4	What rehabilitation or treatment methods are most effective for vision loss following brain damage due to stroke, brain injury, cerebral vision impairment, tumours and dementias?	What are the most effective detection and screening methods for follow up to detect metastasis of ocular melanoma?	Is it possible to prevent further occurrences of retinal damage caused by toxoplasmosis?	Would correction of refractive error have a positive impact on early life learning and development?	Is there a way to improve screening of premature babies for retinopathy of prematurity?	What causes retinal detachment and can it be prevented?
26							
27							
28							
29							
30							
31	5	What is the most effective way to assess vision in patients with neurological visual impairment i.e. stroke, dementia and cerebral/cortical visual impairment?	How can follow-up for ocular complications be managed in patients with ocular melanoma?	What causes birdshot retinopathy?	Does early diagnosis of refractive error improve long-term prognosis and promote faster, more effective treatment?	Can an effective long lasting treatment for diabetic macular oedema, both ischaemic and non-ischaemic, be developed?	Can more effective diagnostic tools be developed for assessing the vitreous and eye floaters?
32							
33							
34							
35	6	Can the early stages of optic neuropathy be detected?	What is the best management of metastatic choroidal melanoma?	Why does disease burn out in patients with ocular and orbital inflammatory diseases?	What is the effect of congenital nystagmus on visual and emotional development?	Can a retinal vein occlusion be predicted and prevented?	Can a functioning prosthetic eye be developed to replace an eye damaged by injury?
36							
37							
38	7	How can optic neuropathies be prevented, for example anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?	What activates choroidal melanoma metastasis in the liver after the primary melanoma has been treated?	Can early detection methods be developed for ocular and orbital inflammatory diseases?	What is the most effective treatment for exotropia and when should it be delivered?	Can new non-invasive treatments be developed to slow down the progression of diabetic retinopathy?	How can epiretinal membrane/fibrosis be prevented or treated?
39							
40							
41							
42							
43	8	Can treatments be developed for visual field and ocular	Can adjuvant therapies be developed to treat ocular	What medications best prevent the development of eye disease in	How can the functional effects of surgical treatment for squint best	What are the barriers that prevent diabetic patients	Can stem cells be used to regrow an eye or part of an eye?
44							
45							
46							
47							
48							
49							

9	motility manifestations following stroke? How can electronic devices improve or restore vision for people with optic neuropathies?	melanoma? What are the causes of ocular cancer and how can they be prevented?	Behcets? What causes scleritis?	be assessed? Could the accurate testing of refractive error be made less dependent on a subjective response i.e. the person's own response?	having regular eye checks? What rehabilitation programmes are best for the management of distorted vision from retinal diseases?	What causes posterior vitreous detachment/vitreous syneresis?
10	Can an alternative or new treatment be developed that will treat the sight loss caused by giant cell arteritis?	What is the most effective treatment for primary ocular melanoma?	Can diet or lifestyle changes prevent uveitis from developing?	How can myopia be prevented?	What is the efficacy and safety of anti-VEGF agents in the treatment of retinopathy of prematurity?	Are there methods to prevent and improve the treatment of macular holes?

Figure legends

Figure 1: Flowchart showing the steps of the process from Stage 1 when establishing the PSP through to Stage 5 at the final prioritisation.

Figure 2: Background of respondents showing that questions were largely received from people who have sight loss or an eye condition, but also including eye health professions, organisations, parents, family and carers.

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): Overview and results of the research prioritisation **survey process.**

Fiona Rowe¹, Richard Wormald^{2,3}, Richard Cable⁴, Michele Acton⁴, Karen Bonstein⁵, Michael Bowen⁶, Carol Bronze⁷, Catey Bunce^{2,3,5}, Dolores Conroy⁴, Katherine Cowan⁸, Kathy Evans⁹, Mark Fenton¹⁰, Heather Giles⁷, Iris Gordon³, Louise Halfhide⁵, Robert Harper¹¹, Anita Lightstone¹², Marcela Votruba¹³, Heather Waterman¹⁴, Antra Zekite²

1. British and Irish Orthoptic Society, London, UK
2. Department of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK
3. The Cochrane Eyes and Vision Group, London School of Hygiene and Tropical Medicine, London, UK
4. Fight for Sight, London, UK
5. NIHR Biomedical Research Centre at Moorfields and UCL Institute of Ophthalmology, London, UK
6. College of Optometrists, London, UK
7. Patient representative
8. The James Lind Alliance (JLA) –National Institute for Health Research, Southampton, UK
9. Royal College of Ophthalmologists, London, UK
10. UK DUETs (NICE Evidence – UK Database of Uncertainties about the Effects of Treatments), London, UK
11. Department of Optometry, Manchester Royal Eye Hospital, Manchester, UK
12. UK Vision Strategy / VISION 2020 UK, London, UK
13. Department of Ophthalmology, Cardiff University, Cardiff, UK
14. Department of Nursing, University of Manchester, Manchester, UK

Corresponding author:

Dr Fiona Rowe

Department of Health Services Research,

1
2
3 WhelanBuilding (1.10),
4

5 University of Liverpool,
6

7 Brownlow Hill,
8

9
10 Liverpool L69 3GB
11

12
13 T: 0151 7944956
14

15 E: rowef@liverpool.ac.uk
16
17
18
19

20 **Word count:** 2573
21

22 **Number of figures:** 2
23

24 **Number of tables:** 3
25

26
27 **Short title:** Sight Loss and Vision Priority Setting Partnership
28

29
30 **Competing interests:** The authors declare that they have no competing interests.
31

32
33 **Funding:** This work was supported through funding and/or in-kind support by
34 College of Optometrists, Fight for Sight, James Lind Alliance, NIHR Moorfields BRC,
35 RNIB, Royal College of Ophthalmologists and UK Vision Strategy.
36
37

38
39 **Author contributions:** FR, RW, RC, MA, KB, MB, CBr, CBu, DC, KC, KE, MF, HG,
40 IG, LH, RH, AL, MV, HW and AZ contributed to the conduct of the survey. FR, RW,
41 RC, MA, MB, DC and KC were involved in the drafting of the paper. KB, CBr, CBu,
42 KE, MF, HG, IG, LH, RH, AL, MV, HW and AZ contributed to proofing of the paper.
43
44

45
46 **Data sharing statement:** All original data are held by Fight for Sight. Extra data is
47 available from: <http://www.library.nhs.uk/duets/SearchResults.aspx?catID=14501>
48 The additional unpublished data includes research questions not included in the final
49 top ten lists of research priorities.
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: The Sight Loss and Vision Priority Setting Partnership aimed to identify research priorities relating to sight loss and vision through consultation with patients, carers and clinicians. These priorities can be used to inform funding bodies' decisions and enhance the case for additional research funding.

Design: Prospective survey with support from the James Lind Alliance.

Setting: UK wide NHS and non-NHS.

Participants: Patients, carers and eye health professionals. Academic researchers were excluded **solely from the prioritisation process**. The survey was disseminated by patient groups, professional bodies, at conferences and through the media, and was available for completion online, by phone, by post and by alternative formats (Braille and audio).

Outcome measure: People were asked to submit the questions about prevention, diagnosis and treatment of sight loss and eye conditions that they most wanted to see answered by research. Returned survey questions were reviewed by a data assessment group. **Priorities** were established across eye disease categories at final workshops.

Results: 2,220 people responded generating 4,461 submissions. Sixty-five percent of respondents had sight loss and/or an eye condition. Following initial data analysis, 686 submissions remained which were circulated for interim prioritisation (excluding cataract and ocular cancer questions) to 446 patients/carers and 218 professionals. The remaining 346 questions were discussed at final prioritisation workshops to reach agreement of top questions per category.

Conclusions: The exercise engaged a diverse community of stakeholders generating a wide range of conditions and research questions. Top priority questions were established across 12 eye disease categories.

Keywords: Sight loss; Vision; Research; Priorities; Partnership; James Lind Alliance

Article summary

Strengths and limitations of this study:

- Wide ranging and comprehensive coverage
- Substantial response
- The hardest to reach and those with the least opportunity to be heard may indeed have not been heard
- Any such groups now feeling excluded should have an opportunity to redress this.

Introduction

In the UK it is estimated that almost 2 million people are affected by sight loss and this number is expected to double by 2050¹. Currently 50% of sight loss in the UK is avoidable but there are also many unavoidable sight loss conditions. Whether it is to address childhood eye conditions or those affecting adults, research is needed to inform us about prevention, to develop new techniques for early diagnosis and to develop new and more effective treatments for many eye conditions.

The Sight Loss and Vision Priority Setting Partnership (SLV-PSP) was developed from earlier work by the Eye Research Group (ERG) of VISION 2020 UK whose mission is the elimination of avoidable sight loss and the amelioration of the effects of sight loss when it cannot be avoided². The UK Vision Strategy sets out ways of addressing avoidable sight loss in the UK. There is much that can be done to improve the nation's eye health, and to eliminate avoidable sight loss. There are however gaps in the evidence base regarding eye health interventions and the best way to deliver services. Research is needed to support the UK Vision Strategy. In key areas research is urgently required to enable the Vision Strategy to be implemented in an evidence-based way that ensures efficient and effective development.

Despite on-going research in the UK and other countries, there are still many questions about the prevention, diagnosis and treatment of sight loss and eye conditions that remain unanswered. Given that resources for research are limited, it

1
2
3 is important for research funders to understand how patients, carers and eye health
4 professionals prioritise these unanswered questions so that future research can be
5 consolidated and targeted accordingly³.
6
7

8
9 The purpose of this project was to undertake a comprehensive, UK-wide, survey of
10 patients, carers and clinicians to identify research questions and priorities to inform
11 decisions of funding bodies and enhance the case for additional research funding.
12
13

14 The priority setting process has been well established by the James Lind Alliance
15 (JLA) (<http://www.lindalliance.org/>) which has supported partnerships on a range of
16 topics since 2004. This partnership initiated by Fight for Sight, the UK's leading eye
17 research charity was established with support, financial and in kind, from the College
18 of Optometrists, the Royal College of Ophthalmologists, the NIHR Moorfields
19 Biomedical Research Centre, the RNIB, UK Vision Strategy and the Cochrane Eyes
20 and Vision Group. A representative from the JLA convened meetings of the steering
21 committee and provided independent chairmanship for this and the priority setting
22 workshops. Their extensive experience in this process ensured no single voice
23 exerted undue influence over the prioritisation process and that the views of patients,
24 their carers and clinicians were paramount. The views of researchers with no clinical
25 involvement with patients and views of commercial organisations were not included
26 in the prioritisation.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Methods and materials**

41
42 The detailed methods for this prioritisation process have been described in detail
43 elsewhere⁴. In brief, the process comprised five stages (figure 1). **Our study did not**
44 **require ethical approval or consent from participants. James Lind Alliance priority**
45 **setting partnerships do not require ethical approval. Dissemination of the survey was**
46 **via open communications through professional bodies, charities and related**
47 **organisations. The survey was not undertaken through Higher Education Institutes or**
48 **through NHS organisations and does not recruit NHS patients. The survey contained**
49 **clear information on the aims of the priority setting partnership, how the process**
50 **works and how data will be used. In addition, submission of questions was**
51 **anonymised. For the workshops in which priorities were discussed and agreed,**
52
53
54
55
56
57
58
59
60

participants choose to voluntarily attend and consent was not required for this. We followed the ethical guidance for participation, information and evaluation from the James Lind Alliance guidebook (<http://www.jla-guidebook.org/jla-guidebook.asp?val=56>).

Establishing the SLV-PSP

A steering committee and data assessment group comprising the authors of this article oversaw the process. Each member was responsible for contributing to and managing a part of the process and was selected for their expertise and association with eye research. The steering committee also included patient representatives and eye health professionals. In April 2012 an initial stakeholder meeting was held to engage the groups and organisations with member bases and community influence. This was to ensure that the initial survey would be disseminated and completed by as many patients, relatives, carers and eye health professionals as possible in the UK.

Main survey

The SLV-PSP survey was launched on 1 May 2012 and was open until 31 July 2012. The aim of the survey was to identify patients', carers' and eye health professionals' unanswered questions about sight loss and eye conditions. The survey's primary question was "What question(s) about the prevention, diagnosis and treatment of sight loss and eye conditions would you like to see answered by research?"

Data analysis

Following closure of the survey, all submissions were examined. Out-of-scope submissions were removed including those not related to the topic and uncertainties better suited to social research. In-scope uncertainties were allocated into disease-specific groups and re-worded in PICO format (Population, Intervention, Comparison, Outcome). Searches were then undertaken to ascertain whether or not each uncertainty could be answered by an up-to-date systematic review. All unanswered uncertainties were then allocated to one of 12 eye disease categories, with duplicates removed and similar questions combined. Checks were also made to identify any on-going trials which might address the uncertainty. The 12 categories

1
2
3 were formed following discussions by the steering group on the most logical and
4 pragmatic way to organise the data within the time and resources available.
5
6

7 ***Interim prioritisation***

8
9
10 In order to start reducing the number of uncertainties, an interim prioritisation
11 exercise was conducted over email and by post. Patients, carers and eye health
12 professionals were invited to examine the long lists and then choose and rank 10 of
13 the uncertainties.
14
15

16 ***Final prioritisation***

17
18
19 The remaining uncertainties were ranked by patients, carers, relatives, organisation
20 representatives and eye health professionals in one-day workshops facilitated by the
21 JLA, using Nominal Group Technique – a mix of discussion and ranking. For each
22 category, the top 10/11 questions were agreed.
23
24
25
26
27
28

29 **Results**

30 ***Main survey***

31
32
33 In response to the survey, 2220 people generated 4461 submissions. Of these
34 respondents, 17% identified themselves as healthcare professionals including
35 primarily ophthalmologists, optometrists, orthoptists, ophthalmic nurses, opticians
36 and people working in social care and rehabilitation (figure 2). Over 60% were
37 people with sight loss or an eye condition. The average age of survey participants
38 was 65.7 years old (range:16 months (proxy completion of survey by adult carer)to
39 105 years). Just under two thirds (62%) of respondents were female. The
40 geographical split was: England 89%; Scotland 6%; Wales 4%; Northern Ireland 1%.
41
42
43
44
45
46
47

48 ***Data analysis***

49
50
51 Following data analysis to remove duplicate/answered/out of scope uncertainties,
52 686 uncertainties remained. These were divided into twelve eye disease categories.
53 Table 1 shows each category with the initial number of submissions received after
54 the survey responses were submitted, the number of uncertainties sent to interim
55
56
57
58
59
60

prioritisation, the number of participants at interim prioritisation and the number of uncertainties considered at the final prioritisation workshops.

Interim prioritisation

Respondents from the initial survey, organisations and eye healthcare professionals with expertise in the eye diseases in ten categories were contacted to provide interim priority rankings. The smaller number of questions asked in the categories relating to cataract and ocular cancer meant that an interim prioritisation exercise was not required for either category. A large response was received for the interim exercise, with input from 446 patients, carers and relatives plus 218 eye health professionals. Uncertainties accumulated scores based on rank and frequency, resulting in short lists of around 30 uncertainties per category which were taken to final workshops.

Final prioritisation

In April and May 2013, 12 final prioritisation workshops were held: one for each eye disease category. Balanced numbers of patients/carers/relatives and eye health professionals participated. In total, 155 participants attended across all 12 workshops: 78 patients and 77 clinicians (table 2). The topics debated at each workshop comprised between 19-31 questions per category. Overall 153 questions about sight loss and vision were considered resulting in lists of 10/11 priorities for each of the 12 categories (table 3). The questions addressed the broad topics of aetiology, prevention, identification and interventions with the number 1 questions as follows:

Age-related macular degeneration

1. Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised?

Cataract

1. How can cataracts be prevented from developing?

Childhood-onset disorders

1. How can cerebral visual impairment be identified, prevented and treated in children?

Corneal and external diseases

1. Can new therapies such as gene or stem cell treatments be developed for corneal diseases?

Glaucoma

1. What are the most effective treatments for glaucoma and how can treatment be improved?

Inherited retinal diseases

1. Can a treatment to slow down progression or reverse sight loss in inherited retinal diseases be developed?

Neuro-ophthalmology

1. What is the underlying cause of optic nerve damage in optic neuropathies, such as anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?

Ocular cancer

1. What can be done to help ocular cancer sufferers?

Ocular inflammatory diseases

1. What are the most effective treatments for ocular and orbital inflammatory diseases?

Refractive error and ocular motility

1. What factors influence the development of refractive error (myopia, astigmatism, presbyopia and long-sightedness)?

Retinal vascular diseases

1. What are the best methods to prevent retinopathy of prematurity?

Vitreoretinal and ocular trauma

1. How can surgical techniques be improved to save sight for eyes damaged by injury?

Discussion

About 50% of sight loss in the UK is currently avoidable¹. Recognising this and the UK's pre-eminent position in eye research, the Vision 2020UK ERG considered that

any UK Research Agenda must look at addressing unavoidable sight loss for it to be credible. The challenge was to produce a coherently constructed and constituted prioritised research agenda whose methods were clear and for which there had been inclusive and widespread consultation, where everyone with an interest had been offered the opportunity to contribute and be heard. **As a result of this priority setting partnership we have established top ten lists of research questions for a range of eye conditions.**

There are a number of strengths to this study. The SLV-PSP is unique because it sought the combined views of patients, carers and eye health professionals to identify uncertainties about the prevention, diagnosis and treatment of sight loss and eye conditions and prioritise them for research to address⁵. It is rare that those with direct experience of conditions are able to influence the research agenda^{3,5,6}. **The views of patients, carers and professionals were given equal merit. All submitted questions were evaluated independently and equally. Duplicate questions and out of scope questions were removed. We did not encounter particular misunderstandings between lay persons and professionals or insufficient knowledge of the public. Open discussions occurred during the face-to-face workshops with good communication and facilitation to encourage respectful listening in accordance with James Lind Alliance guidelines. Questions could only be pooled if this was agreed by patients, carers and professionals. Where there was no agreement, the questions remained separate. Thus, any differing perspectives of priorities between participants were acknowledged. We did not aim to compare and contrast questions from patients, carers and professionals but to represent and act on all.**

This SLV-PSP provided an extensive set of unanswered questions prioritised by patients, carers and eye health professionals across twelve categories of eye conditions. These questions addressed a broad range of eye conditions and considered issues of aetiology, prevention, screening, assessment and management. **Importantly, the public were as likely to propose questions in relation to aetiology, assessment and management just as professionals were as likely to raise questions regarding impact of sight loss.**

In addition to the strengths of our study, we identified a number of limitations. We were unable to calculate a response rate for the survey because of the nature of its

1
2
3 design and implementation. We did not request the views of 'pure' researchers (i.e.
4 scientists with no current clinical practice) as these individuals are intentionally
5 excluded from the priority setting process by the James Lind Alliance. This step is a
6 key feature of the James Lind Alliance methodology in which the remit is to provide
7 an opportunity for patients, carers and clinicians to influence the research agenda.
8 We acknowledge this is a different approach but do not consider their exclusion as a
9 flaw in this process as we include clinical researchers who did take part alongside
10 clinicians and the public.
11

12
13
14
15
16
17 These questions may now be used to encourage researchers to investigate what is
18 most important to these groups. We do not know how our research questions
19 compare to the prioritisation of research areas by scientists, government agencies or
20 other organisation research funders. We are unaware of any systematic data
21 collating such data.
22

23
24
25 Various organisations in the sector have set out priorities for eye health and eye
26 research in the past, for example Vision2020UK⁷. In addition, organisations
27 representing the interests of patients/carers and eye health professionals took part in
28 the process, both in promoting the survey and being directly involved in priority
29 setting. Future work to review the SLV-PSP projects priorities with these
30 organisations could be helpful in developing an understanding of how these new,
31 patient and clinician led priorities can inform the sectors approach to commissioning
32 research and focusing resources. Organisations in the sector are already working to
33 review their organisational priorities with the SLV priorities, and have begun to invite
34 researchers seeking funding to consider how their proposed research relates to the
35 SLV priorities.
36
37

38
39
40
41
42
43
44 Similar to other PSP processes, we have provided information on our research
45 priorities openly to national funding organisations and it is envisaged that research
46 funders will be able to use the list to inform commissioned calls for research and
47 identify which research applications to response mode funding opportunities can
48 answer questions that these groups have agreed are a priority. Furthermore, any
49 questions or uncertainties not prioritised in this process were submitted to and are
50 currently available on the UK Database of Uncertainties about the Effects of
51 Treatments (UK DUETs). Thus individuals looking for uncertainties for their research
52
53
54
55
56
57
58
59
60

1
2
3 can access such information direct from UK DUETs. This sharing of information
4 contributes to the quality assurance process of avoiding waste in research.
5
6

7 The SLV-PSP will also help to increase awareness of why research into sight loss
8 and vision is necessary and important. It will be used to campaign for major funders
9 to invest in sight loss and eye conditions, all of which are placing increased
10 emphasis on researchers demonstrating how they have consulted and involved the
11 public and patients in the process of developing their research.
12
13
14

15
16 These remain significant goals. For a sector with around 700 organisations to arrive
17 at any kind of consensus for research priority areas, a process that was genuinely
18 consultative, open and engaging to the individuals whose interests these
19 organisations represent as well as at an organisational level was recognised as
20 being critical. For a prioritisation exercise to be useful to the sector it needed to
21 make sense to funders and statutory bodies with responsibilities and interests in
22 these areas as well as to researchers. It was recognised that a prioritisation of
23 research areas produced by a small group within the sector would not be credible
24 and would never engage the support required for it to achieve the goals listed above.
25
26
27
28
29
30
31
32
33
34

35 **Conclusions**

36
37 Following a systematic process of national consultation and widespread survey of
38 patients, carers and clinicians, 2220 individuals generated 4461 questions. Through
39 a process of data analysis, interim prioritisation and final workshops, a top ten or
40 eleven research questions have been identified for twelve categories of eye
41 conditions. This is the first time, to our knowledge, that an exercise like this has been
42 carried out anywhere in the world for sight loss and vision. Not only is this the most
43 wide ranging and ambitious James Lind Alliance priority setting partnership, it also
44 engaged a diversity of participants and enabled them to reach consensus together.
45 For the first time, we have a clear idea of what the consumers of eye research – the
46 patients and the people who care for and treat them – believe research money
47 should be spent on. It has provided a focus for research in sight loss and vision and
48 it is intended that these priorities are used to inform funders, researchers, clinicians
49 and the public.
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1: Flowchart showing the steps of the process from Stage 1 when establishing the PSP through to Stage 5 at the final prioritisation.

Figure 2: Background of respondents showing that questions were largely received from people who have sight loss or an eye condition, but also including eye health professions, organisations, parents, family and carers.

References

1. Access Economics (2009) Future Sight Loss UK 1: The economic impact of partial sight and blindness in the UK adult population, RNIB
2. <http://www.vision2020uk.org.uk/>
3. Chalmers, I. and Glasziou, P. (2009) 'Avoidable waste in the production and reporting of research evidence', *The Lancet*, Vol. 374, pp. 86–89.
4. Sight loss and vision priority setting partnership. Setting priorities for eye research. (2013) Final report. www.sightlosspsp.org.uk
5. Stewart, R. and Oliver, S. (2008) *A systematic map of studies of patients' and clinicians' research priorities*. London: James Lind Alliance.
6. Caron-Flinterman J, et al. (2006) Patients priorities concerning health research: the case of asthma and COPD research in the Netherlands. *Health Expectations*, 8, pp253–263.
7. UK Vision Strategy 2013-2018. www.vision2020uk.org.uk

Table 1 Categories of eye condition

	Initial number of survey questions	Number of questions at interim prioritisation	Number of participants at interim prioritisation	Number of questions at final prioritisation
Age-related macular degeneration	763	43	101 PPI 25 Professionals	29
Cataract	191	27	Not required	27
Childhood-onset disorders	125	69	12 PPI 20 Professionals	30
Corneal and external diseases	292	93	25 PPI 38 Professionals	30
Glaucoma	1235	78	182 PPI 25 Professionals	30
Inherited retinal diseases	280	63	27 PPI 25 Professionals	30
Neuro-ophthalmology	125	43	15 PPI 21 Professionals	30
Ocular cancer	26	19	Not required	19
Ocular inflammatory diseases	472	66	27 PPI 21 Professionals	30

Refractive error and ocular motility	188	70	21 PPI 23 Professionals	31
Retinal vascular diseases	205	56	15 PPI 12 Professionals	30
Vitreoretinal and ocular trauma	265	59	21 PPI 8 Professionals	30

PPI: Inclusive of patients, carers, relatives, organisation representatives.

Professionals: Inclusive of eye health professions.

Table 2 Final workshop participants

Category	Total number of workshop participants	Number of patients, relatives, carers, patient groups and organisations	Number of eye health professionals
Age-related Macular Degeneration	17	9	8
Cataract	11	5	6
Childhood-Onset Disorders	16	7	9
Corneal and External Diseases	12	5	7
Glaucoma	17	9	8
Inherited Retinal Diseases	19	11	8
Neuro-ophthalmology	10	6	4
Ocular Cancer	10	6	4
Ocular Inflammatory Diseases	10	5	5
Refractive Error and Ocular Motility	12	5	7
Retinal Vascular Diseases	11	3	8
Vitreoretinal and Ocular Trauma	10	7	3
TOTAL	155	78	77

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 3 Top ten lists per category

	Age-related macular degeneration	Cataract	Childhood-onset disorders	Corneal and external diseases	Glaucoma	Inherited retinal diseases
1	Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised? What is the cause of AMD?	How can cataracts be prevented from developing?	How can cerebral visual impairment be identified, prevented and treated in children?	Can new therapies such as gene or stem cell treatments be developed for corneal diseases?	What are the most effective treatments for glaucoma and how can treatment be improved? How can loss of vision be restored for people with glaucoma?	Can a treatment to slow down progression or reverse sight loss in inherited retinal diseases be developed? How can sight loss be prevented in an individual with inherited retinal disease?
2	How can AMD be prevented?	Can the return of cloudy or blurred vision after cataract surgery known as posterior capsule opacity (PCO) or secondary cataract be prevented? How can cataract progression be slowed down?	How can treatment for visual pathway damage associated with pre-term birth be developed?	What is the most effective management for dry eye and can new strategies be developed?	How can glaucoma be stopped from progressing?	Is a genetic (molecular) diagnosis possible for all inherited retinal diseases?
3	Are there ways of restoring sight loss for people with AMD?	What alternatives to treat cataracts other than cataract surgery are being developed?	How do we improve screening and surveillance from the ante-natal period through to childhood to ensure early diagnosis of impaired vision and eye conditions?	Can treatments to save eye sight from microbial keratitis be improved?	What can be done to improve early diagnosis of sight-threatening glaucoma?	What factors affect the progression of sight loss in inherited retinal diseases?
4	Can the development of AMD be predicted?	What is the cause of cataract?	Can the treatment of amblyopia be improved to produce better short and long term outcomes than are possible with current treatments?	How can the rejection of corneal transplants be prevented?	What causes glaucoma?	What causes sight loss in inherited retinal diseases?
5	What is the most effective way to detect and monitor the progression of early AMD?	How can cataract surgery outcomes be improved?	How can cataract be prevented in children?	Can the outcomes of corneal transplantation be improved?	What is the most effective way of monitoring the progression of glaucoma?	What is the most effective way to support patients with inherited retinal disease?
6	What factors influence the progression of AMD?	How safe and effective is laser assisted cataract surgery?	What are the causes of coloboma and microphthalmia/anophthalmia and how can they be prevented?	Can non-surgical therapy be developed for Fuchs' corneal dystrophy?	How can glaucoma patients with a higher risk to progress rapidly be detected?	Can the diagnosis of inherited retinal diseases be refined so that individuals can be given a clearer idea about their specific condition and how it is likely to progress?
7	Can a non-invasive therapy be developed for wet AMD?	Should accommodative lenses be developed for cataract surgery?	Can vision be corrected in later life for people with amblyopia?	How can retinoblastoma be identified, prevented and treated in children?	Why is glaucoma more aggressive in people of certain ethnic groups, such as those of West African origin?	What is the relationship between sight loss and mental health for people with inherited retinal diseases?
8	Can dietary factors, nutritional supplements, complementary therapies or lifestyle changes prevent or slow the progression of AMD?	What is the best measure of visual disability due to cataract?	Can better treatments for glaucoma in children be developed?	What is the cause of keratoconus and can it be prevented?	How can glaucoma be prevented?	Would having a treatment for an inherited retinal disease preclude a patient from having another treatment?
9	What are the best enablement strategies for people with AMD?	Can retinal detachment be prevented after cataract surgery?	Can a treatment be developed to improve vision for people with albinism?	What is the most effective management of ocular complications associated with Stevens Johnson Syndrome?	Is there a link between treatment adherence and glaucoma progression and how can adherence be improved?	With regard to inherited retinal diseases what is the role of pre-natal and pre-implantation diagnosis in helping parents make informed choices?
10		What are the outcomes for cataract surgery among people with different levels of cognitive		Can severe ocular surface disease in children, such as blepharokeratoconjunctivitis and		


		impairment (all causes excluding dementia, stroke, neurological conditions, head injuries)?		vernal keratoconjunctivitis be managed better?		
	Neuro-ophthalmology	Ocular cancer	Ocular inflammatory diseases	Refractive error and ocular motility	Retinal vascular diseases	Vitreoretinal and ocular trauma
1	What is the underlying cause of optic nerve damage in optic neuropathies, such as anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?	What can be done to help ocular cancer sufferers?	What are the most effective treatments for ocular and orbital inflammatory diseases?	What factors influence the development of refractive error (myopia, astigmatism, presbyopia and long-sightedness)?	What are the best methods to prevent retinopathy of prematurity?	How can surgical techniques be improved to save sight for eyes damaged by injury?
2	What are the most effective treatments and rehabilitation for optic neuropathies, e.g. Leber's hereditary optic neuropathy and anterior ischaemic optic neuropathy?	Can gene-based targeted therapies for ocular cancers be developed?	What causes thyroid eye disease?	What is the cause of both congenital and acquired nystagmus?	How can sight loss from diabetic retinal changes be prevented and reduced?	How can the risk of losing sight for people with retinal detachment be reduced?
3	Can vision loss due to optic nerve diseases such as giant cell arteritis, Leber's hereditary optic neuropathy, optic neuritis and optic atrophy, be restored, for example through gene therapy and stem cell treatment?	How can immunotherapy be used to fight metastatic ocular melanoma?	Can the severity of ocular and orbital inflammatory disease in an individual be predicted?	How can the development of binocular vision in young children with squint and amblyopia be promoted, and would the same approach work in older individuals without inducing intractable diplopia?	What are the predictive factors for the progression to sight threatening diabetic eye disease?	How can better interventions be developed that are effective in treating vitreous opacities/eye floaters?
4	What rehabilitation or treatment methods are most effective for vision loss following brain damage due to stroke, brain injury, cerebral vision impairment, tumours and dementias?	What are the most effective detection and screening methods for follow up to detect metastasis of ocular melanoma?	Is it possible to prevent further occurrences of retinal damage caused by toxoplasmosis?	Would correction of refractive error have a positive impact on early life learning and development?	Is there a way to improve screening of premature babies for retinopathy of prematurity?	What causes retinal detachment and can it be prevented?
5	What is the most effective way to assess vision in patients with neurological visual impairment i.e. stroke, dementia and cerebral/cortical visual impairment?	How can follow-up for ocular complications be managed in patients with ocular melanoma?	What causes birdshot retinopathy?	Does early diagnosis of refractive error improve long-term prognosis and promote faster, more effective treatment?	Can an effective long lasting treatment for diabetic macular oedema, both ischaemic and non-ischaemic, be developed?	Can more effective diagnostic tools be developed for assessing the vitreous and eye floaters?
6	Can the early stages of optic neuropathy be detected?	What is the best management of metastatic choroidal melanoma?	Why does disease burn out in patients with ocular and orbital inflammatory diseases?	What is the effect of congenital nystagmus on visual and emotional development?	Can a retinal vein occlusion be predicted and prevented?	Can a functioning prosthetic eye be developed to replace an eye damaged by injury?
7	How can optic neuropathies be prevented, for example anterior ischaemic optic neuropathy, Leber's hereditary optic neuropathy, optic neuritis and other optic neuropathies?	What activates choroidal melanoma metastasis in the liver after the primary melanoma has been treated?	Can early detection methods be developed for ocular and orbital inflammatory diseases?	What is the most effective treatment for exotropia and when should it be delivered?	Can new non-invasive treatments be developed to slow down the progression of diabetic retinopathy?	How can epiretinal membrane/fibrosis be prevented or treated?
8	Can treatments be developed for visual field and ocular	Can adjuvant therapies be developed to treat ocular	What medications best prevent the development of eye disease in	How can the functional effects of surgical treatment for squint best	What are the barriers that prevent diabetic patients	Can stem cells be used to regrow an eye or part of an eye?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

9	motility manifestations following stroke? How can electronic devices improve or restore vision for people with optic neuropathies?	melanoma? What are the causes of ocular cancer and how can they be prevented?	Behcets? What causes scleritis?	be assessed? Could the accurate testing of refractive error be made less dependent on a subjective response i.e. the person's own response?	having regular eye checks? What rehabilitation programmes are best for the management of distorted vision from retinal diseases?	What causes posterior vitreous detachment/vitreous syneresis?
10	Can an alternative or new treatment be developed that will treat the sight loss caused by giant cell arteritis?	What is the most effective treatment for primary ocular melanoma?	Can diet or lifestyle changes prevent uveitis from developing?	How can myopia be prevented?	What is the efficacy and safety of anti-VEGF agents in the treatment of retinopathy of prematurity?	Are there methods to prevent and improve the treatment of macular holes?

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>


Figure 1 Flowchart of SLVPSP process



90x116mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



313x236mm (96 x 96 DPI)

Review only